WO2000000469A2 - Alkyl ketones as potent anti-cancer agents - Google Patents

Alkyl ketones as potent anti-cancer agents Download PDF

Info

Publication number
WO2000000469A2
WO2000000469A2 PCT/US1999/014758 US9914758W WO0000469A2 WO 2000000469 A2 WO2000000469 A2 WO 2000000469A2 US 9914758 W US9914758 W US 9914758W WO 0000469 A2 WO0000469 A2 WO 0000469A2
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine
chloromethyl ketone
ketone
cys
dodecyl
Prior art date
Application number
PCT/US1999/014758
Other languages
French (fr)
Other versions
WO2000000469A3 (en
Inventor
Fatih M. Uckun
Rama K. Narla
David A. Perry
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Priority to CA002336108A priority Critical patent/CA2336108A1/en
Priority to AU48459/99A priority patent/AU754086B2/en
Priority to JP2000557230A priority patent/JP2002519341A/en
Priority to EP99932068A priority patent/EP1091934A2/en
Publication of WO2000000469A2 publication Critical patent/WO2000000469A2/en
Publication of WO2000000469A3 publication Critical patent/WO2000000469A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/48—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Definitions

  • the present invention relates to alkyl ketone compounds effective for treating tumor cells and particularly effective to induce apoptosis in leukemia cells, breast cancer cells, prostate cancer cells, and brain cancer cells.
  • Cancer is a major disease that continues as one of the leading causes of death at any age. In the United States alone, it is anticipated that more than a half a million Americans will die of cancer in 1999. Currently, radiotherapy and chemotherapy are two important methods used in the treatment of cancer.
  • Novel alkyl ketone compounds have been found to be potent cytotoxic agents with potent activity against cancer cells.
  • certain alkyl ketone compounds were found to exhibit potent cytotoxic activity, particularly against human breast cancer and leukemic cell lines, at micromolar concentrations. These compounds were also effective in inhibiting adhesion and invasion by cancer cells.
  • the present invention includes novel compounds and compositions having potent cytotoxic activity.
  • the present invention also includes methods for treating tumors by administering to a subject an effective amount of a compound of the invention to inhibit growth and/or induce apoptosis of tumor cells.
  • Compositions of the invention contain an effective cytotoxic or inhibitory amount of a compound.
  • the compounds of the invention have the following formula I:
  • R 1 is H, hydroxyl, (C, - C 30 ) alkyl, (Q - C 30 ) alkenyl, (d - C 30 ) haloalkyl, (d - C 30 ) diazoalkyl, , -CH 2 O-C(O)R 5 , -NR 6 R 7 , or -CH 2 -S- R 9 wherein R 5 is independently aryl, (d - C 30 ) alkyl, (Ci - C 30 ) haloalkyl, (Ci - C 30 ) alkenyl, (Ci - C 30 ) diazoalkyl, (Q - C 24 ) cycloalkyl, or (Ci - C 24 ) cycloalkenyl,
  • R 6 is independently H, (d - C 30 ) alkyl, (Ci - C 30 ) haloalkyl, (Ci - C 30 ) diazoalkyl, (Ci - C 30 ) alkenyl, (Ci - C 30 ) haloalkenyl, (Ci - C 2 ) cycloalkyl, or (Ci - C 2 ) cycloalkenyl;
  • R 7 is -OR 8 , R 8 is independently (Ci - C 30 ) alkyl, (Ci - C 30 ) haloalkyl, (Ci - C 30 ) diazoalkyl, (Ci - C 30 ) alkenyl, (Ci - C 30 ) haloalkenyl, (Ci - C 2 ) cycloalkyl, or (Ci - C 24 ) cycloalkenyl;
  • R 9 is independently (Ci - C 30 ) alkyl, (d - C 30 ) haloalkyl, (Ci - C 30 ) diazoalkyl, (Ci - C 30 ) alkenyl, (Ci - C 30 ) haloalkenyl, (C. - C 24 ) cycloalkyl, (Ci - C 24 ) cycloalkenyl, or -R 10 CO 2 H;
  • R 10 is (Ci - C 30 ) alkyl or (Ci - C 30 ) alkenyl, R 2 is Ci or C 2 ; CH 2 or CH 2 CH 2
  • R 3 is (C, - C 30 ) alkyl, (Q - C 30 ) haloalkyl, (d - C 30 ) alkenyl, (Ci - C 30 ) haloalkenyl, (Ci - C 2 ) cycloalkyl, (Ci - C 24 ) cycloalkenyl, (Ci - C 24 )aryl, anthroquinonylmethyl, naphthylmethyl, -SR , or -CR ;
  • R 11 is independently (Q - C 30 ) alkyl, (d - C 30 ) haloalkyl, (d - C 30 ) alkenyl, or (Ci - C 0 ) haloalkenyl;
  • R is aryl substituted methyl;
  • R 4 is H, -C(O)R 13 , or -C(O)-O-R 14 ;
  • R 13 and R 14 are each independently (Ci
  • Preferred compounds of the invention are those where p is the integer 1, R is a haloalkyl, R 2 is Ci, R 3 is a (Ci - C 22 ) alkyl, and R 4 is acetyl. Most preferred is the compound N-Ac-S-dodecyl-Cys chloromethyl ketone (HI— 131).
  • Figure 1A is a graph showing survival of primary cancer cells taken from six children with leukemia and treated with different concentrations of compound HI— 131 as a function of drug concentration.
  • Figure IB is a graph showing mean survival as a function of drug concentration from the data of Figure 1 A.
  • Figures 2A-2F show photographs of apoptosis induced by HI-131 in treated human Leukemia cells.
  • FIG. 1A NALM-6 control
  • Figure 2B HI-131 treated NALM-6 cells
  • FIG. 1 UPN1 control
  • Figure 2D HI-131 treated UPN1 cells
  • FIG.E UPN2 control
  • Figure 2F HI-131 treated UPN2 cells.
  • Figure 3 is a bar graph showing induction of apoptosis by HI-131 in treated primary leukemic cells and established NALM-6 and MOLT-3 cell lines.
  • Figure 4 is a bar graph showing inhibition of invasive properties of human MDA-MB-231 breast cancer cells by HI-131.
  • Figure 5 is a graph showing inhibition of the invasive properties of human U373 (glioblastoma) brain tumor cells by HI-131.
  • Figure 6 is a graph showing inhibition of the adhesion of human MDA-
  • MB-231 breast tumor cells by HI-131 MB-231 breast tumor cells by HI-131.
  • Figure 7 is a graph showing inhibition of the adhesion by human U373 (glioblastoma) cells by HI-131. Detailed Description of the Invention
  • the present invention includes novel alkyl ketone compounds having potent activity as cytotoxic agents.
  • the compounds of the invention are useful agents for inhibiting growth or inducing apoptosis in tumor cells, for example, leukemia and breast tumor cells.
  • alkyl includes both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. As a preferred embodiment, chains of 1 to 22 carbon atoms are included.
  • alkene includes both branched and straight chain aliphatic hydrocarbon groups that have at least one double bond.
  • alkoxy includes, saturated and unsaturated, branched and straight chain aliphatic hydrocarbon groups having a specified number of carbon atoms where at least one carbon atom forms a single-bond to an oxygen atom.
  • amine includes primary, secondary, and tertiary amines.
  • halogen or “halo” substituent includes fluoro, chloro, bromo, and iodo.
  • pharmaceutically acceptable salt thereof includes an acid addition salt or a base salt.
  • pharmaceutically acceptable carrier includes any material which, when combined with a compound of the invention, allows the compound to retain biological activity, such as the ability to induce apoptosis of leukemia or breast tumor cells, and is non-reactive with the subject's immune system.
  • examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsions, and various types of wetting agents.
  • Compositions comprising such carriers are formulated by well known conventional methods (see, for example, Remington's Pharmaceutical Sciences, Chapter 43, 14th Ed., Mack Publishing Co., Easton, PA).
  • Substituted cycloalkyl includes cyclic hydrocarbons having substituents including halo, alkyl, alkenyl, oxyalkyl, oxyalkenyl, haloalkyl, haloalkenyl, and aryl.
  • “Substituted cycloalkenyl” includes cyclic hydrocarbons having at least one double bond where substituents include halo, alkyl, alkenyl, oxyalkyl, oxyalkenyl, haloalkyl, haloalkenyl, and aryl.
  • Substituted aryl includes aromatic hydrocarbons having substituents including hydroxyl, amino, aminomethyl, halo, alkyl, alkenyl, oxyalkyl, oxyalkenyl, haloalkyl, haloalkenyl, and aryl.
  • Treating in the context of this invention means the prevention or reduction in severity of symptoms or effects of a pathological condition, including prolonging life expectancy.
  • treatment includes prevention of tumor growth, reduction of tumor size, enhanced tumor cell death, and increased apoptosis.
  • novel alkyl ketone compounds of the invention have the general structure represented by the following formula I:
  • X is O or S
  • R 1 is H, hydroxyl, (Ci - C 30 ) alkyl, (Ci - C 30 ) alkenyl, (d - C 30 ) haloalkyl, (d - C 30 ) diazoalkyl, , -CH 2 O-C(O)R 5 , -NR 6 R 7 , or -CH 2 -S-
  • R y wherein R 5 is independently aryl, (d - C 30 ) alkyl, (d _ C 30 ) haloalkyl, (Ci - C 30 ) alkenyl, (Cj - C 30 ) diazoalkyl, (Ci - C 24 ) cycloalkyl, or (Ci - C 2 ) cycloalkenyl, R 6 is independently H, (Ci - C 30 ) alkyl, (C, - C 30 ) haloalkyl, (Q -
  • C 30 diazoalkyl, (C ⁇ - C 30 ) alkenyl, (Ci - C 30 ) haloalkenyl, (Ci - C 4 ) cycloalkyl, or (Ci - C 24 ) cycloalkenyl;
  • R 7 is -OR 8 , R 8 is independently (Ci - C 30 ) alkyl, (Ci - C 30 ) haloalkyl, (Ci - C 30 ) diazoalkyl, (Ci - C 30 ) alkenyl, (d - C 30 ) haloalkenyl, (d - C 24 ) cycloalkyl, or (Ci - C2 4 ) cycloalkenyl;
  • R 9 is independently (Ci - C 30 ) alkyl, (Ci - C 30 ) haloalkyl, (Ci - C 30 ) diazoalkyl, (Ci - C 30 ) alkenyl, (Ci ⁇ C 30 ) haloalkenyl, (Ci - C 24 ) cycloalkyl, (Ci - C 24 ) cycloalkenyl, or -R 10 CO 2 H;
  • R 10 is (Ci - C 30 ) alkyl or (Ci - C 30 ) alkenyl
  • R 2 is d or C 2 ; CH 2 or CH 2 CH 2
  • R 3 is (d - C 30 ) alkyl, (d - C 30 ) haloalkyl, (d - C 30 ) alkenyl, (d - C 30 ) haloalkenyl, (Ci - C 2 ) cycloalkyl, (Cj - C 24 ) cycloalkenyl, (Ci - C 24 )aryl, anthroquinonylmethyl, naphthylmethyl, -SR , or -CR ;
  • R 11 is independently (Ci - C 30 ) alkyl, (Ci - C 30 ) haloalkyl, (Ci - C 0 ) alkenyl, or (d _ C 30 ) haloalkenyl;
  • R is aryl substituted methyl;
  • R 4 is H, -C(O)R 13 , or -C(O)-O-R 14 ;
  • R 13 and R 14 are each independently (Q - C ⁇ 2 ) alkyl, (Ci - Cj ) haloalkyl, (Ci - C ⁇ 2 ) alkenyl, (Ci - C ⁇ 2 ) haloalkenyl, (C 3 - C 12 ) cycloalkyl, or (C 3 - C ⁇ 2 ) cycloalkenyl; or a pharmaceutically acceptable acid addition salt thereof.
  • the compounds of formula I are useful for the treatment of cancer, particularly the treatment of leukemia and breast cancer. In the method of the invention, a therapeutic amount of a compound of formula I is administered to a patient for the treatment of cancer.
  • a preferred compound of the invention has the structure of formula II:
  • a preferred embodiment of the compound of Formula II is that shown as having formula III, where X is S, R 3 is dodecyl, and R 4 is acetyl:
  • R 1 is most preferably chloromethyl;
  • R 2 is preferably CH 2 ;
  • R 3 is preferably a C 12 alkyl;
  • R 4 is preferably acetyl; and
  • X is preferably S.
  • a most preferred compound of formula II is N- Ac-S-dodecy 1-Cys chloromethyl ketone (HI- 131).
  • Preferred compounds of the invention having potent anti-cancer affects are the following:
  • N-Ac-S-dodecyl-Cys chloromethyl ketone HI-131
  • N-Ac-S-pentyl-cysteine chloromethyl ketone HI-224
  • N-Ac-S-octyl-cysteine chloromethyl ketone HI-352
  • N-Ac-S-tetradecyl-cysteine chloromethyl ketone HI-354
  • N-Ac-S-hexadecyl-cysteine chloromethyl ketone (HI-366); N-Ac-S-tr ⁇ ra— tr ans-farnesyl-Cys diazomethyl ketone (HI-367);
  • N-Ac-S-benzyloxycarbonyl-cysteine chloromethyl ketone (HI-389); N-Ac-S-2-naphthylmethyl-cysteine chloromethyl ketone (HI-392);
  • N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488); N-Ac-O-dodecyl-serine chloromethyl ketone (HI-489); N-Trifluoroacetyl-S-dodecyl-cysteine chloromethyl ketone (HI-490); N-Benzoyl-S-dodecyl-cysteine chloromethyl ketone (HI-491).
  • Base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
  • metals used as cations are sodium, potassium, magnesium, calcium, and the like.
  • heavy metal salts such as for example silver, zinc, cobalt, and cerium.
  • suitable amines are N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamene, N-methylglucamine, and procaine.
  • Pharmaceutically acceptable acid addition salts are formed with organic and inorganic acids.
  • suitable acids for salt formation are hydrochloric, suliuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, gluconic, fumaric, succinic, ascorbic, maleic, methanesulfonic, and the like.
  • the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce either a mono or di, etc. salt in the conventional manner.
  • the free base forms may be regenerated by treating the salt form with a base. For example, dilute solutions of aqueous base may be utilized.
  • Dilute aqueous sodium hydroxide, potassium carbonate, ammonia, and sodium bicarbonate solutions are suitable for this purpose.
  • the free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for the purposes of the invention.
  • the compounds of the invention are effective cytotoxic agents, for example, against tumor cells such as leukemic and breast cancer cells.
  • the cytotoxic effects of alkyl ketone compounds are achieved by contacting cells, such as tumor cells, with micromolar amounts of the inhibitory compound.
  • a particularly useful anti-tumor agent is N- Ac-S- dodecy 1-Cys chloromethyl ketone (HI-131) as shown in the Examples below.
  • the compounds of the invention can be used in methods of tumor treatment, for example, by administering to a subject a compound of the invention in order to achieve an inhibition of tumor cell growth, a killing of tumor cells, induction of apoptosis, and/or increased patient survival time.
  • cytotoxic compounds of the invention are suitable for use in mammals.
  • mammals means any class of higher vertebrates that nourish their young with milk secreted by mammary glands, including, for example, humans, rabbits, and monkeys.
  • Apoptosis or programmed cellular death, is an active process requiring new protein synthesis. Typically, the process requires ATP, involves new RNA and protein synthesis, and culminates in the activation of endogenous endonucleases that degrade the DNA of the cell, thereby destroying the genetic template required for cellular homeostasis.
  • Apoptosis is observed in controlled deletion of cells during metamorphosis, differentiation, and general cell turnover and appears normally to be regulated by receptor-coupled events. For these reasons, apoptosis has been called "programmed cell death" or "cell suicide.” While every cell likely has the genetic program to commit suicide, it is usually suppressed. Under normal circumstances, only those cells no longer required by the organism activate this self-destruction program.
  • Apoptotic cell death is characterized by plasma membrane blebbing, cell volume loss, nuclear condensation, and endonucleolytic degradation of DNA at nucleosome intervals. Loss of plasma membrane integrity is a relatively late event in apoptosis, unlike the form of cell death termed necrosis, which can be caused by hypoxia and exposure to certain toxins and which is typically characterized, early-on by increased membrane permeability and cell rupture. As demonstrated in the Examples, the alkyl ketone compounds of the invention are effective agents for inducing apoptosis in tumor cells.
  • the compounds of the present invention can be formulated as pharmaceutical compositions and administered to a mammalian host, including a human patient, in a variety of forms adapted to the chosen route of administration.
  • the compounds are preferably administered in combination with a pharmaceutically acceptable carrier, and may be combined with or conjugated to specific delivery agents, including targeting antibodies and/or cytokines.
  • the compounds can be administered by known techniques, such as orally, parentally (including subcutaneous injection, intravenous, intramuscular, intrasternal or infusion techniques), by inhalation spray, topically, by absorption through a mucous membrane, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants or vehicles.
  • Pharmaceutical compositions of the invention can be in the form of suspensions or tablets suitable for oral administration, nasal sprays, creams, sterile injectable preparations, such as sterile injectable aqueous or oleagenous suspensions or suppositories.
  • compositions can be prepared according to techniques well-known in the art of pharmaceutical formulation.
  • the compositions can contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents.
  • the compositions can contain microcrystalline cellulose, starch, magnesium stearate and lactose or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
  • compositions can be prepared according to techniques well-known in the art of pharmaceutical formulation.
  • the compositions can be prepared as solutions in saline, using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons or other solubilizing or dispersing agents known in the art.
  • compositions can be formulated according to techniques well-known in the art, using suitable dispersing or wetting and suspending agents, such as sterile oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable dispersing or wetting and suspending agents such as sterile oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • compositions can be prepared by mixing with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ambient temperatures, but liquefy or dissolve in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ambient temperatures, but liquefy or dissolve in the rectal cavity to release the drug.
  • Preferred administration routes include orally, parenterally, as well as intravenous, intramuscular or subcutaneous routes.
  • the compounds of the present invention are administered parenterally, i.e., intravenously or intraperitoneally, by infusion or injection.
  • the compounds may be administered directly to a tumor by tumor injection; or by systemic delivery by intravenous injection.
  • Solutions or suspensions of the compounds can be prepared in water, isotonic saline (PBS) and optionally mixed with a nontoxic surfactant. Dispersions may also be prepared in glycerol, liquid polyethylene, glycols, DNA, vegetable oils, triacetin and mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical dosage form suitable for injection or infusion use can include sterile, aqueous solutions or dispersions or sterile powders comprising an active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol such as glycerol, propylene glycol, or liquid polyethylene glycols and the like, vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size, in the case of dispersion, or by the use of nontoxic surfactants.
  • the prevention of the action of microorganisms can be accomplished by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, buffers, or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the inclusion in the composition of agents delaying absorption — for example, aluminum monosterate hydrogels and gelatin.
  • Sterile injectable solutions are prepared by incorporating the conjugates in the required amount in the appropriate solvent with various other ingredients as enumerated above and, as required, followed by filter sterilization.
  • the preferred methods of preparation are vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
  • the compound of the invention can be targeted for specific delivery to the cells to be treated by conjugation of the compounds to a targeting moiety.
  • Targeting moiety useful for conjugation to the compounds of the invention include antibodies, cytokines, and receptor ligands expressed on the cells to be treated.
  • conjugate means a complex formed with two or more compounds.
  • targeting moiety means a compound which serves to deliver the compound of the invention to a specific site for the desired activity.
  • Targeting moieties include, for example, molecules which specifically bind molecules present on a cell surface.
  • Such targeting moieties useful in the invention include anti-cell surface antigen antibodies.
  • Cytokines, including interleukins, factors such as epidermal growth factor (EGF), and the like, are also specific targeting moieties known to bind cells expressing high levels of their receptors.
  • Particularly useful targeting moieties for targeting the compounds of the invention to cells for therapeutic activity include those ligands that bind antigens or receptors present on the tumor cells to be treated.
  • antigens present on B-lineage cancer cells such as CD 19, can be targeted with anti-CD 19 antibodies such as B43.
  • Antibody fragments, including single chain fragments, can also be used.
  • IL4 can also be used to target B-cells.
  • Cancer cells expressing EGF or IGF receptors can be targeted with the binding ligand.
  • Other such ligand-receptor binding pairs are known in the scientific literature for specific cancers. Methods for producing conjugates of the compounds of the invention and the targeting moieties are known.
  • the administered dose is that effective to have the desired effect, such as sufficient to reduce or eliminate tumors.
  • Appropriate amounts can be determined by those skilled in the art, extrapolating using known methods and relationships, from the in vitro data provided in the Examples.
  • the dose of the novel alkyl ketone compounds effective to achieve tumor cell apoptosis, reduction in tumors, and increased survival time is 1-100 mg/kg body weight/dose for a direct targeted administration.
  • the effective dose to be administered will vary with conditions specific to each patient. In general, factors such as the disease burden, tumor location (exposed or remote), host age, metabolism, sickness, prior exposure to drugs, and the like contribute to the expected effectiveness of a drug. One skilled in the art will use standard procedures and patient analysis to calculate the appropriate dose, extrapolating from the data provided in the Examples. In general, a dose which delivers about 1-100 mg/kg body weight is expected to be effective, although more or less may be useful.
  • compositions of the invention may be administered in combination with other anti-tumor therapies.
  • the administered dose of the alkyl ketone compounds may be less than for single drug therapy.
  • Tables 3 and 6 and the compounds in Tables 4 and 5 are also described in detail below. All chemicals were purchased from Aldrich Chemical Company (Milwaukee, Wisconsin) and used directly for synthesis without further purification. Anhydrous tetrahydrofuran was dried over sodium and distilled immediately prior to use. Column chromatography was performed using 230-400 mesh silica gel obtained from the Merck Company, with eluant as noted in the experimental procedure.
  • the first step of scheme 1 was isoprenylation of the thiol group of N ⁇ Ac- Cys-OH by reaction of the appropriate isoprenyl bromide in a 4 M solution of ammonia in methanol according to the method of Brown and co-workers. This step was carried out in the presence of ethyl acetate when N-Ac-Cys-OH was dodecylated in order to solvate the bromododecane.
  • the S- alkylated acid (2a) was activated as the mixed anhydride derivative using isobutylchloroformate and converted to the diazomethyl ketone (3 a) by treatment with diazomethane.
  • the diazomethane was converted to the chloromethyl ketone (4a) with HCI in ethyl acetate at 0 °C for 10 minutes.
  • the chloromethyl compounds in Tables 1 and 2, 4a-4g, were made from the analogous diazomethyl compounds, 3a-3g, by replacement of the diazomethyl group with a chloromethyl group. The specific synthesis of each two member analogous group will therefore be considered together.
  • N-Ac-Cys-OH (1) (0.82 g, 5 mmol) in 4 M ammonia in methanol (35 mL) at 0 °C.
  • the reaction was stirred at 0 °C for 3 h then at room temperature for 1 h.
  • the solvent was removed under reduced pressure and the residue partitioned between 1- butanol and water.
  • the butanol layer was dried (MgSO 4 ) and the solvent removed under reduced pressure.
  • the residue was redissolved in methanol and washed with hexane.
  • the methanol was then removed under reduced pressure to give N-Ac-S- trans- traws-farnesyl-Cys-OH (2a).
  • N-Ac-S-rrar ⁇ -/r ⁇ «s-farnesyl-Cys-OH (2a) (1.84 g, 5 mmol) produced in the previous step was dissolved in dry THF (30 mL) and cooled to - 15 °C. 4-methyl morpholine (0.51 g, 0.55 mL, 5 mmol) and z ' so-butyl chloroformate (0.68 g, 0.65 mL, 5 mmol) were added to the solution. The mixture was stirred at -15 °C for 5 minutes before being filtered by gravity into a solution of diazomethane in ethanolic ether (11 mmol, 30 mL) cooled in an ice bath.
  • N-Ac-S- r ⁇ «s-geranyl-Cys-OH (2c) was prepared as described above for N-Ac-S-tttms-frOra-farnesyl-Cys-OH (2a) except that trans-geranyl bromide was used instead of farnesyl bromide.
  • N-Ac-S-fr- ⁇ —geranyl-Cys diazomethyl ketone (HI 122) (3c) was prepared as described above for N-AcS-tr ⁇ ns-tr ⁇ ns-famesy 1-Cys diazomethyl ketone (3 a) except that N-Ac-S-/r ⁇ r ⁇ -geranyl-Cys-OH (2c) (2.99 g, 10 mmol) was used instead of N-Ac-S-fr" ⁇ «s-/r ⁇ r ⁇ -farnesyl-Cys-OH (2a).
  • N-Ac-S-fr- ⁇ r ⁇ — geranyl-Cys chloromethyl ketone (HI 127) (4c) was prepared as described above for N-Ac-S-tr ⁇ ns- tr ⁇ ns-famesy ⁇ -Cys chloromethyl ketone (4a) except that N-Ac-S-fr- ⁇ r ⁇ -geranyl-Cys diazomethyl ketone (3c) (0.10 g, 0.3 mmol) was used instead of ⁇ N- AcS-tr ⁇ ns- trans- famesy 1-Cys diazomethyl ketone (3a).
  • N-Ac-S-(3-methyl-2-butenyl)-Cys-OH (2d) was prepared as described above for N-Ac-S-tr ⁇ s—fr ⁇ TM-farnesyl-Cys-OH (2a) except that 4-bromo-2- methyl-2-butene was used instead of farnesyl bromide.
  • N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (3d) was prepared as described above for N-Ac-S-tr ⁇ ns-tr ⁇ ns-famesy ⁇ -Cys diazomethyl ketone (3a) except that N-Ac-S-(3-methyl-2-butenyl)-Cys-OH (2d) (0.69 g, 3 mmol) was used instead of N-AcS-trans- trans- farnesyl-Cys-OH (2a).
  • N-Ac-S-(3-methyl-2-butenyl)-Cys chloromethyl ketone (4d) was prepared as described above for ⁇ N-Ac-S-trans-trans-farnesy ⁇ -Cys chloromethyl ketone (4a) except that N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (3d) (0.30 g, 1.2 mmol) was used instead of N-Ac-S-tr ⁇ fls-tr ⁇ ra-farnesyl-Cys diazomethyl ketone (3a).
  • N-Ac-Cys-OH (1.62 g, 9.9 mmol) and bromododecane (2.5 g, 10 mmol) were dissolved in a mixture of ethyl acetate (30 mL) and methanol (20 mL).
  • the solvent was then removed under reduced pressure and the residue was partitioned between ethyl acetate and 1 M HCI.
  • the organic layer was dried over MgSO and the solvent removed under reduced pressure to give N-Ac-S-dodecyl-Cys-OH (2e).
  • N-Ac-S-dodecyl-Cys diazomethyl ketone (3e) was prepared as described above for N-AcS-trans- trans-famesy 1-Cys diazomethyl ketone (3a) except that N-Ac-S-dodecyl-Cys-OH (2e) (0.96 g, 2.9 mmol) was used instead ofN-Ac-S- trans- trans-famesyl-Cys-OH (2a).
  • the crude product was purified by chromatography on silica gel (1 :3 ethyl acetate/hexane) to give N-Ac-S-dodecyl- Cys diazomethyl ketone (3e).
  • N-Ac-S-dodecyl-Cys chloromethyl ketone (4e) was prepared as described above for N-Ac-S-farnesyl-Cys chloromethyl ketone (4a) except that N-Ac-S- dodecyl-Cys diazomethyl ketone (3e) (0.19 g, 0.5 mmol) was used instead of N- Ac-S-tr ⁇ ns- tr ⁇ ns-famesy 1-Cys diazomethyl ketone (3a). N-Ac-S-dodecyl-Cys chloromethyl ketone (4e) was obtained after removal of solvent. 5. N-Boc-S-farnesyl-Cys diazomethyl ketone (HI-82) (3b) and N-Boc-S-farnesyl-Cys chloromethyl ketone (HI-124) (4b)
  • S-tr ⁇ r ⁇ - ⁇ r ⁇ r ⁇ -Farnesyl-mercaptoethyl diazomethyl ketone (3f) was prepared as described above for N-AcS-trans-trans-famesy 1-Cys diazomethyl ketone (3a) except that 3-(S-tr ⁇ ns- trans- Farnesyl)-mercaptopropionic acid (2f) was used instead of N-Ac-S-t w- tr ans-famesyl-Cys-OH (2a).
  • S-tr ra-?r ⁇ /75—Farnesyl-mercaptomethyl diazomethyl ketone (3g) was prepared as described above for N-Ac-S-tr ⁇ ns- trans- famesy 1-Cys diazomethyl ketone (3a) except that S- rar ⁇ - ⁇ r ⁇ ra-Farnesyl-mercaptoacetic acid (2g) (0.71 g, 2.4 mmol) was used instead of N-Ac-S-fr ⁇ ra , -fr" ⁇ ms , -farnesyl-Cys-OH (2a).
  • the first step in scheme 2 was the dodecylation of cysteine methyl ester in a mixture of ethyl acetate and methanol. This was followed by Boc-protection, ester hydrolysis and conversion in turn to the chloromethyl ketone (8).
  • S-Dodecyl-Cys chloromethyl ketone hydrochloride (9) was prepared from N-Boc-S-dodecyl-Cys chloromethyl ketone (8), by simply deprotecting the Boc group in a saturated solution of HCI in ethyl acetate.
  • Boc-S-dodecyl-Cys-OCH 3 was obtained after removal of solvent.
  • N-Boc-S-dodecyl-Cys diazomethyl ketone was prepared as described above for N-AcS-trans- trans-famesy 1-Cys diazomethyl ketone (3 a) except that N-Boc-S-dodecyl-Cys-OH (7) (0.89 g, 2.3 mmol) was used instead of N-Ac-S- trans- trans- farnesyl-Cys-OH (2a).
  • the crude product was purified by chromatography on silica gel (1:2 ethyl acetate/hexane) to give N-Boc-S-dodecyl-
  • N-Boc-S-dodecyl-Cys chloromethyl ketone (8) was prepared as described above for N-Ac-S-tr ⁇ r ⁇ -fr- ⁇ r ⁇ —farnesyl-Cys chloromethyl ketone (4a) except that N-Boc-S-dodecyl-Cys diazomethyl ketone (0.56 g, 1.4 mmol) was used instead of N-Ac-S-tr ⁇ , -fr * ⁇ — farnesyl-Cys diazomethyl ketone (3a). N-Boc-S-dodecyl- Cys chloromethyl ketone (8) was obtained upon removal of solvent.
  • the first step in scheme 3 was the farnesylation of cysteine methyl ester according to the method of Brown et al.
  • the farnesylated cysteine methyl ester was then coupled with N-Boc-Gly-OH using EDC/HOBt.
  • the ester was hydrolyzed to the acid (11) and the chloromethyl ketone prepared via the diazomethyl ketone (12).
  • N-Boc-Gly-S- r ⁇ r ⁇ - ⁇ rara-farnesyl-Cys-OCH (1.25 g, 2.52 mmol) was dissolved in methanol (70 mL) and then a solution of NaOH (3 M, 2.5 mL, 7.56 mmol) at 0 °C was added. The solution was stirred overnight at the same temperature. The solvent was then removed and the residue was dissolved in water (50 mL) that was subsequently acidified to pH 5.
  • N-Boc-Gly-S-fr-flra—tr ⁇ ra-farnesy 1-Cys diazomethyl ketone (12) was prepared as described above for N- Ac-S-tr ans- trans- famesy 1-Cys chloromethyl ketone (4a) except that N-Boc-Gly-S- ⁇ s-frara'-farnesyl-Cys-OH (11) (0.39 g, 0.8 mmol) was used instead of N-AcS-tr ⁇ ns-tr ⁇ ns-farnesy ⁇ -Cys diazomethyl ketone (3a).
  • N-Boc-Gly-S- r ra- fr ⁇ ra-farnesyl-Cys chloromethyl ketone (13) was prepared as described above for N-Ac-S-tr ⁇ —tr ⁇ «s-farnesy 1-Cys chloromethyl ketone (4a) except that N-Boc-Gly-S-fr ⁇ r ⁇ -tra/75-farnesy 1-Cys diazomethyl ketone (0.21 g, 0.41 mmol) was used instead of ⁇ -Ac-S-tr ⁇ ns- r ⁇ ns-fa esyl-Cys diazomethyl ketone (3 a).
  • the straight chain alkyl ketone derivatives (4h-y) were synthesized by a modification of the standard literature procedure. Previously, the standard conditions for making diazomethyl ketones were used, but a closer study of the dodecyl derivative, N-Ac-S-dodecyl-Cys chloromethyl ketone (4e), showed significant formation of the methyl ester as a side-product. Presumably, the mixed anhydride intermediate either could not completely form or was hydrolyzed back to the acid before the diazomethane could react with it. Conducting the mixed anhydride formation at -78 °C increased the stability and longevity of the mixed anhydride and improved yield.
  • NMM (0.20 g, 0.22 mL, 2 mmol) and isobutyl chloroformate (0.27 g, 0.26 mL, 2 mmol) was added to the desired N-Ac-S-alkyl-cysteine (2 mmol) in anhydrous THF (20 mL) that had been cooled to -78 °C. The solution was then stirred at -78 °C for 20 min. A solution of diazomethane in ethanolic ether (10 mL) was carefully added and the solution allowed to slowly warm to room temperature. Further portions of diazomethane solution were added until a yellow color persisted.
  • the solution was diluted with ether, washed with water and sodium bicarbonate solution and then dried over anhydrous MgSO .
  • the solvent was removed under reduced pressure to yield the crude diazomethyl ketone compound.
  • the diazomethyl ketone was dissolved in ethyl acetate (20 mL) and cooled in an ice bath.
  • a solution of HCI in ethyl acetate (2M, 2 mL) was added and the solution stirred in ice for 5 min until no more diazomethyl ketone could be observed by TLC.
  • the solvent was removed under reduced pressure and the residue purified by chromatography on silica gel (ethyl acetate/hexane) to give the pure chloromethyl ketone compounds in Table 3 and Table 6.
  • the aldehyde (HI-274) was made from the acid (HI- 208, 2e) via formation of the Weinreb amide (HI-267) by activation of the acid as its' mixed anhydride followed by coupling with N,O-dimethylhydroxylamine.
  • the aldehyde was then synthesized by reduction of the Weinreb amide using LiAlFL.
  • the thiomethyl ketones (HI-269, 302, 399, 365 & 273) were made by displacement of the halogen of the bromo or chloromethyl ketones with the appropriate thiol in the presence of potassium carbonate in DMF.
  • the serine derivative (HI-266) was synthesized by reaction of Boc-Ser-OH with sodium hydride and 1-bromododecane in DMF to give the N-Boc-O- dodecyl-Ser-OH and then with isobutylchloroformate/diazomethane and HCI in ethyl acetate at 0 °C as in the chemistry noted above.
  • the acetyl serine derivative (HI-489) was synthesized from HI-266 by removal of the Boc group in saturated HCI in ethyl acetate followed by acetylation using acetic anhydride in dichloromethane in the presence of triethylamine.
  • NMR spectra were recorded using a 300 MHz Varian instrument and the chemical shifts reported are in ppm based on tetramethylsilane as the internal standard. Chemical shifts for 13 C NMR are referenced to the chloroform peak at 77.0 ppm. Melting points were done using a Fisher-Jones apparatus and are uncorrected. Fourier Transform Infra-red spectra were recorded on a FT-Nicolet model Protege 460 instrument. GC/MS analysis was done using a Hewlett-Packard GC/MS model 6890 with an HP5973 electron impact mass spectrometer.
  • N-Ac-S-trityl-cysteine chloromethyl ketone (HI-350) Pale yellow solid: 1H NMR (CDC1 3 ) ⁇ 1.92 (s, 3H), 2.73 (m, 2H), 3.89 (s, 2H), 4.40 (m, IH), 5.82 (d, IH), 7.21 (m, 15H).
  • N-Ac-S-2-naphthylmethyl-cysteine chloromethyl ketone HI-392
  • N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488) Pale yellow solid: ⁇ NMR (CDC1 3 ) ⁇ 0.84 (t, 3H), 1.22 (m, 18H), 1.53 (m, 2H), 2.02 (s, 3H), 2.50 (t, 2H), 2.92 (m, 2H), 4.12 (s, 2H), 4.89 (m, IH), 6.44 (d, IH).
  • N-Ac-S-dodecyl-Cys-N(OCH 3 )-CH 3 (HI-267) Pale yellow oil: ⁇ NMR (CDCI 3 ) ⁇ 0.87 (t, 3H), 1.25 (m, 20H), 2.02 (s, 3H), 2.51 (t, 2H), 2.82 (m, 2H), 3.22 (s, 3H), 3.79 (s, 3H), 5.17 (m, IH), 6.38 (d, IH); MS (El) m/z 314 (M - N(OCH 3 )CH 3 ).
  • N-Ac-S-dodecyl-Cys-CH 2 -SPh (HI-269) Pale yellow solid: 1H NMR (CDCI 3 ) ⁇ 0.88 (t, 3H), 1.25 (m, 18H), 1.53 (m, 2H), 1.97 (s, 3H), 2.46 (t, 2H), 2.2 (m, 2H), 5.16 (m, IH), 5.43 (s, 2H), 6.16 (d, IH), 7.33 (s, 5H).
  • N-Ac-S-dodecyl-Cys-CH 2 -S-2-naphthyl (HI-302) Pale yellow solid:
  • Cytotoxicity of alkyl ketone compounds The cytotoxicity of the alkyl ketone compounds against tumor cells was evaluated in leukemic cells, breast cancer cells, prostate cancer cells, and brain cancer cells.
  • Cytotoxicity of various compounds against tumor cells was performed using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Boehringer Mannheim Corp., Indianapolis, IN). Unless otherwise specified, all cell lines were obtained from the American Type Culture Collection (ATCC). Briefly, exponentially growing cells were seeded into a 96-well plate at a density of 2.5 x 10 4 cells/well and incubated for 36 hours at 37°C prior to drug exposure. On the day of treatment, culture medium was carefully aspirated from the wells and replaced with fresh medium containing the indicated compound at concentrations ranging from 0.1 to 250 ⁇ M. Triplicate wells were used for each treatment. Human leukemic cell lines (NALM-6, MOLT-3) glioblastoma cells
  • the absorbence of each well was measured in a microplate reader (Labsystems) at 540 nm and a reference wavelength of 690 nm.
  • the OD 5 0 values were compared to those on standard OD 540 - versus - cell number curves generated for each cell line. The percent survival was calculated using the formula:
  • a series of compounds was prepared with different aliphatic chain lengths in the R 3 position to determine the effect of chain length on cytotoxicity. As shown in Table 3, compounds with chain lengths of about 5 to 15 were the most effective anti-cancer agents. Preferred lengths were chain lengths of about 11 to 12. Various groups were tested in the R 1 position to further define effective anti- cancer compounds. The results are reported in Table 4. Substitution of a bromomethyl group at the R 1 position produced the most effective compound, consistent with Table I where chloromethyl was the most effective compound. The effect of changing of X and R 4 on cytotoxicity was examined and reported in Table 5.
  • Cytotoxicity of HI-131 in Primary Cancer Cells The cytotoxicity of HI-131 against primary cancer cells was evaluated in leukemia cells taken from six children ( Figure 1 A), using the MTT assay described for Example 3. The cells were exposed to HI-131 at concentrations ranging from 0 to 50 ⁇ M. Percent survival was calculated as described for Example 3 and plotted against the HI-131 concentration used in the experiment. A composite concentration survival curve was then prepared from the data ( Figure IB).
  • HI-131 Induces Apoptosis of Leukemia Cells
  • the ability of HI-131 to induce apoptosis cells was evaluated in human leukemia in NALM-6 cells and primary leukemic cells from 2 patients. Cells were treated with 50 ⁇ M compound HI-131 for 24 hours. After incubatin, the cells were harvested and analyzed for apoptosis by in situ TUNNEL analysis and confocal laser scanning microscopy as described in Sudbeck et al., 1999, Clin. Cancer Res., 5:1589-82. Controls were treated with vehicle alone.
  • HI-131 The ability of HI-131 to inhibit invasion by MDA-MB-231 breast cancer cells and U373 glioblastoma cells was evaluated.
  • the coated inserts were rehydrated with 0.5 ml serum-free DMEM containing 0.1% bovine serum albumin for 1-2 hours.
  • serum-free DMEM containing 0.1% bovine serum albumin
  • exponentially growing cells were incubated overnight with HI-131 at various concentrations ranging from 1 ⁇ M to 25 ⁇ M and 2.5 ⁇ M to 25 ⁇ M, respectively.
  • the cells were trypsinized, washed twice with serum-free DMEM containing BSA, counted and resuspended at 1 x 10 5 cells/ml.
  • a cell suspension containing 5 x 10 4 cells in a serum-free DMEM containing HI-131 or vehicle was added to the Matrigel-coated and rehydrated filter inserts.
  • 750 ⁇ l of NIH fibroblast conditioned medium was placed as a chemoattractant in 24-well plates and the inserts were placed in wells and incubated at 37°C for 48 hours. After the incubation period, the filter inserts were removed, the medium was decanted off and the cells on the top side of the filter that did not migrate were scraped off with a cotton-tipped applicator. The invasive cells that migrated to the lower side of the filter were fixed, stained with Hema-3 solutions and counted under microscope.
  • IC 50 values were calculated by non-linear regression analysis using Graphpad Prisin Software Version 2.0 (Graphpad Software Inc., San Diego, CA).
  • MDA-MB-231 breast cancer cells and U373 glioblastoma cells were highly invasive in Matrigel-coated Boyden chambers.
  • HI- 131 inhibited the invasion of both MDA-MB-231 breast cancer cells and U373 glioblastoma cells through the Matrigel matrix in dose-dependent fashion.
  • ECM proteins such as laminin, fibronectin, and type IV collagen are thought to play an important role in tumor cell attachment and migration.
  • Laminin, fibronectin and collagen have been found in the basal lamina of blood vessels and in the glial limitans externa in the brain that promote the adhesion and invasion of tumor cells in situ (Carbonetto, 1984, Trends Neurosci., 7:382-387; Rutkaet al. J. Neurosurg, 69:155-170; Venstrom, et al, 1993, FASEB J, 7:996-1003).
  • the effects of these ECM proteins on integrin- mediated U373 glioblastoma and MDA-MB-231 cell adhesion was examined.
  • a human brain tumor cell line derived from an adult patient with glioblastoma, U-373 MG (Cat. #HTB-17) and MDA-MB-231 breast cancer cells (Cat. #HTB-26) were obtained from American Type Culture Collection (ATCC, Manassas, VA) and maintained in liquid culture using DMEM supplemented with 10% fetal bovine serum and antibiotics.
  • Fibroblast conditioned medium was used as a source of chemoattractant in vitro invasion assays.
  • Conditioned medium was prepared as described previously (Albini, et al, 1987, Cancer Res., 47:3239-3245). For the preparation of this conditioned medium NIH/3T3 embryonic fibroblasts (ATCC cat.
  • DMSO 0.05%> trypsin (Life Technologies) resuspended in DMEM, incubated at 37°C for 2 hours to allow them to recover from the trypsinization stress and examined for their ability to adhere to plates precoated with ECM proteins.
  • adhesion assays cells were centrifuged, washed twice with serum-free DMEM, counted and resuspended in serum-free DMEM to a final concentration of 2.5 x 10 cells/ml. One hundred ⁇ l of the cell suspension containing 2.5x 10 cells were added to each well and cells were allowed to adhere for 1 hour at 37°C in a humidified 5% CO 2 atmosphere. The adherent fraction was quantitated using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays.
  • MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
  • the OD 5 0 values were compared to those on standard OD 54 o-versus-cell number curves generated for each cell line.
  • the adherent fraction of cells treated with HI-131 was compared to the DMSO-treated control cells and the percent adhesion relative to the control was determined.

Abstract

Novel alkyl ketone compounds having potent cytotoxic activity are described as antitumor agents and are particularly effective against leukemia and breast tumor cells. The compounds of the invention have formula (I), wherein R1-R4, X and p have the meanings given in the description.

Description

ALKYL KETONES AS POTENT ANTI-CANCERAGENTS
Field of the Invention
The present invention relates to alkyl ketone compounds effective for treating tumor cells and particularly effective to induce apoptosis in leukemia cells, breast cancer cells, prostate cancer cells, and brain cancer cells.
Background of the Invention
Cancer is a major disease that continues as one of the leading causes of death at any age. In the United States alone, it is anticipated that more than a half a million Americans will die of cancer in 1999. Currently, radiotherapy and chemotherapy are two important methods used in the treatment of cancer.
Considerable efforts are underway to develop new chemotherapeutic agents for more potent and specific anti-cancer therapy, presenting effective and efficient cytotoxicity against tumor cells, with minimal interference with normal cell function. Accordingly, there is an urgent need for the development and analysis of novel, effective anti-cancer agents.
Summary of the Invention
Novel alkyl ketone compounds have been found to be potent cytotoxic agents with potent activity against cancer cells. For example, certain alkyl ketone compounds were found to exhibit potent cytotoxic activity, particularly against human breast cancer and leukemic cell lines, at micromolar concentrations. These compounds were also effective in inhibiting adhesion and invasion by cancer cells.
Accordingly, the present invention includes novel compounds and compositions having potent cytotoxic activity. The present invention also includes methods for treating tumors by administering to a subject an effective amount of a compound of the invention to inhibit growth and/or induce apoptosis of tumor cells. Compositions of the invention contain an effective cytotoxic or inhibitory amount of a compound. The compounds of the invention have the following formula I:
Figure imgf000004_0001
wherein p is an integer selected from 0 and 1 ; X is O or S; R1 is H, hydroxyl, (C, - C30) alkyl, (Q - C30) alkenyl, (d - C30) haloalkyl, (d - C30) diazoalkyl, , -CH2 O-C(O)R5, -NR6R7, or -CH2 -S- R9 wherein R5 is independently aryl, (d - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) alkenyl, (Ci - C30) diazoalkyl, (Q - C24) cycloalkyl, or (Ci - C24) cycloalkenyl,
R6 is independently H, (d - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C2 ) cycloalkyl, or (Ci - C2 ) cycloalkenyl; R7 is -OR8, R8 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C2 ) cycloalkyl, or (Ci - C24) cycloalkenyl;
R9 is independently (Ci - C30) alkyl, (d - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (C. - C24) cycloalkyl, (Ci - C24) cycloalkenyl, or -R10CO2H;
R10 is (Ci - C30) alkyl or (Ci - C30) alkenyl, R2 is Ci or C2; CH2 or CH2CH2
R3 is (C, - C30) alkyl, (Q - C30) haloalkyl, (d - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C2 ) cycloalkyl, (Ci - C24) cycloalkenyl, (Ci - C24)aryl, anthroquinonylmethyl, naphthylmethyl, -SR , or -CR ; R11 is independently (Q - C30) alkyl, (d - C30) haloalkyl, (d - C30) alkenyl, or (Ci - C 0) haloalkenyl; R is aryl substituted methyl; R4 is H, -C(O)R13, or -C(O)-O-R14; R13 and R14 are each independently (Ci - C12) alkyl, (Ci - C12) haloalkyl, (d - d2) alkenyl, (Ci - Cι2) haloalkenyl, (C3 - Cι2) cycloalkyl, or (C - C12) cycloalkenyl; or a pharmaceutically acceptable acid addition salt thereof. Preferred compounds of the invention are those where p is the integer 1, R is a haloalkyl, R2 is Ci, R3 is a (Ci - C22) alkyl, and R4 is acetyl. Most preferred is the compound N-Ac-S-dodecyl-Cys chloromethyl ketone (HI— 131).
Brief Description of the Drawings
Figure 1A is a graph showing survival of primary cancer cells taken from six children with leukemia and treated with different concentrations of compound HI— 131 as a function of drug concentration.
Figure IB is a graph showing mean survival as a function of drug concentration from the data of Figure 1 A.
Figures 2A-2F show photographs of apoptosis induced by HI-131 in treated human Leukemia cells.
Figure 2A. NALM-6 control;Figure 2B. HI-131 treated NALM-6 cells;
Figure 2C. UPN1 control; Figure 2D. HI-131 treated UPN1 cells;
Figure 2E. UPN2 control; Figure 2F. HI-131 treated UPN2 cells.
Figure 3 is a bar graph showing induction of apoptosis by HI-131 in treated primary leukemic cells and established NALM-6 and MOLT-3 cell lines.
Figure 4 is a bar graph showing inhibition of invasive properties of human MDA-MB-231 breast cancer cells by HI-131.
Figure 5 is a graph showing inhibition of the invasive properties of human U373 (glioblastoma) brain tumor cells by HI-131. Figure 6 is a graph showing inhibition of the adhesion of human MDA-
MB-231 breast tumor cells by HI-131.
Figure 7 is a graph showing inhibition of the adhesion by human U373 (glioblastoma) cells by HI-131. Detailed Description of the Invention
The present invention includes novel alkyl ketone compounds having potent activity as cytotoxic agents. The compounds of the invention are useful agents for inhibiting growth or inducing apoptosis in tumor cells, for example, leukemia and breast tumor cells.
Definitions
All scientific and technical terms used in this application have meanings commonly used in the art unless otherwise specified. As used in this application, the following words or phrases have the meanings specified.
As used herein, "alkyl", includes both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. As a preferred embodiment, chains of 1 to 22 carbon atoms are included.
As used herein, "alkene", includes both branched and straight chain aliphatic hydrocarbon groups that have at least one double bond.
As used herein, "alkoxy", includes, saturated and unsaturated, branched and straight chain aliphatic hydrocarbon groups having a specified number of carbon atoms where at least one carbon atom forms a single-bond to an oxygen atom.
As used herein "amine", includes primary, secondary, and tertiary amines. As used herein "halogen" or "halo" substituent includes fluoro, chloro, bromo, and iodo.
As used herein, "pharmaceutically acceptable salt thereof includes an acid addition salt or a base salt.
As used herein, "pharmaceutically acceptable carrier" includes any material which, when combined with a compound of the invention, allows the compound to retain biological activity, such as the ability to induce apoptosis of leukemia or breast tumor cells, and is non-reactive with the subject's immune system. Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsions, and various types of wetting agents. Compositions comprising such carriers are formulated by well known conventional methods (see, for example, Remington's Pharmaceutical Sciences, Chapter 43, 14th Ed., Mack Publishing Co., Easton, PA).
"Substituted cycloalkyl" includes cyclic hydrocarbons having substituents including halo, alkyl, alkenyl, oxyalkyl, oxyalkenyl, haloalkyl, haloalkenyl, and aryl. "Substituted cycloalkenyl" includes cyclic hydrocarbons having at least one double bond where substituents include halo, alkyl, alkenyl, oxyalkyl, oxyalkenyl, haloalkyl, haloalkenyl, and aryl.
"Substituted aryl" includes aromatic hydrocarbons having substituents including hydroxyl, amino, aminomethyl, halo, alkyl, alkenyl, oxyalkyl, oxyalkenyl, haloalkyl, haloalkenyl, and aryl.
"Treating" or "Treatment" in the context of this invention means the prevention or reduction in severity of symptoms or effects of a pathological condition, including prolonging life expectancy. In the context of cancer therapy, treatment includes prevention of tumor growth, reduction of tumor size, enhanced tumor cell death, and increased apoptosis.
Compounds of the Invention
The novel alkyl ketone compounds of the invention have the general structure represented by the following formula I:
Figure imgf000007_0001
wherein p is O or l;
X is O or S;
R1 is H, hydroxyl, (Ci - C30) alkyl, (Ci - C30) alkenyl, (d - C30) haloalkyl, (d - C30) diazoalkyl, , -CH2 O-C(O)R5, -NR6R7, or -CH2 -S-
Ry wherein R5 is independently aryl, (d - C30) alkyl, (d _ C30) haloalkyl, (Ci - C30) alkenyl, (Cj - C30) diazoalkyl, (Ci - C24) cycloalkyl, or (Ci - C2 ) cycloalkenyl, R6 is independently H, (Ci - C30) alkyl, (C, - C30) haloalkyl, (Q -
C30) diazoalkyl, (C\ - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C 4) cycloalkyl, or (Ci - C24) cycloalkenyl;
R7 is -OR8, R8 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (d - C30) haloalkenyl, (d - C24) cycloalkyl, or (Ci - C24) cycloalkenyl;
R9 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci ~ C30) haloalkenyl, (Ci - C24) cycloalkyl, (Ci - C24) cycloalkenyl, or -R10CO2H;
R10 is (Ci - C30) alkyl or (Ci - C30) alkenyl,
R2 is d or C2; CH2 or CH2CH2
R3 is (d - C30) alkyl, (d - C30) haloalkyl, (d - C30) alkenyl, (d - C30) haloalkenyl, (Ci - C2 ) cycloalkyl, (Cj - C24) cycloalkenyl, (Ci - C24)aryl, anthroquinonylmethyl, naphthylmethyl, -SR , or -CR ;
R11 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C 0) alkenyl, or (d _ C30) haloalkenyl;
19
R is aryl substituted methyl; R4 is H, -C(O)R13, or -C(O)-O-R14; R13 and R14 are each independently (Q - Cι2) alkyl, (Ci - Cj ) haloalkyl, (Ci - Cι2) alkenyl, (Ci - Cι2) haloalkenyl, (C3 - C12) cycloalkyl, or (C3 - Cι2) cycloalkenyl; or a pharmaceutically acceptable acid addition salt thereof. The compounds of formula I are useful for the treatment of cancer, particularly the treatment of leukemia and breast cancer. In the method of the invention, a therapeutic amount of a compound of formula I is administered to a patient for the treatment of cancer.
A preferred compound of the invention has the structure of formula II:
Figure imgf000009_0001
A preferred embodiment of the compound of Formula II is that shown as having formula III, where X is S, R3 is dodecyl, and R4 is acetyl:
Figure imgf000009_0002
R1 is most preferably chloromethyl; R2 is preferably CH2; R3 is preferably a C12 alkyl; R4 is preferably acetyl; and X is preferably S. A most preferred compound of formula II is N- Ac-S-dodecy 1-Cys chloromethyl ketone (HI- 131).
Another embodiment of the invention is a compound of formula IV:
Figure imgf000009_0003
(IV) Preferred compounds of the invention having potent anti-cancer affects are the following:
S-fr"ύrø-fr*α — Farnesyl-mercaptoethyl diazomethyl ketone (HI-83);
N-Boc-S-farnesyl-Cys chloromethyl ketone (HI- 124); S- rørø- røns-Farnesyl-2-mercaptoethyl chloromethyl ketone (H 125);
N-Ac-S-(3-methyl-2-butenyl)-Cys chloromethyl ketone (HI- 128);
N-Boc-S-dodecy 1-Cys chloromethyl ketone (HI- 129);
N-Boc-Gly-S- α -- αrø-farnesyl-Cys chloromethyl ketone (HI-130);
N-Ac-S-dodecyl-Cys chloromethyl ketone (HI-131); N-Ac-S-pentyl-cysteine chloromethyl ketone (HI-224);
N-Ac-S-pentadecyl-cysteine chloromethyl ketone (HI-225);
S-Dodecyl-Cys chloromethyl ketone hydrochloride (HF-252);
N-Ac-S-heptyl-cysteine chloromethyl ketone (HI-263);
N-Ac-S-dodecyl-Cys-H (HI-274); N-Ac-S-methyl-cysteine chloromethyl ketone (HI-314);
N-Ac-S-undecyl-cysteine chloromethyl ketone (HI-321);
N-Ac-S-dodecyl-Cys diazomethyl ketone (HI-348);
N-Ac-S-trityl-cysteine chloromethyl ketone (HI-350);
N-Ac-S-octyl-cysteine chloromethyl ketone (HI-352); N-Ac-S-tetradecyl-cysteine chloromethyl ketone (HI-354);
N-Ac-S-hexyl-cysteine chloromethyl ketone (HI-357);
N-Ac-S-butyl-cysteine chloromethyl ketone (HI-363);
N-Ac-S-nonyl-cysteine chloromethyl ketone (HI-364);
N-Ac-S-hexadecyl-cysteine chloromethyl ketone (HI-366); N-Ac-S-trøra— tr ans-farnesyl-Cys diazomethyl ketone (HI-367);
N-AcS-trans- trans-farnesy 1-Cys chloromethyl ketone (HI-368);
N-Ac-S-propyl-cysteine chloromethyl ketone (HI-369);
N-Ac-S-decyl-cysteine chloromethyl ketone (HI-371);
N-Ac-S-benzyloxycarbonyl-cysteine chloromethyl ketone (HI-389); N-Ac-S-2-naphthylmethyl-cysteine chloromethyl ketone (HI-392);
N— 9— Fluorenylmethyloxycarbonyl— S— dodecyl— cysteine chloromethyl ketone (HI-
398);
N-Ac-S-allyl-cysteine chloromethyl ketone (HI-419);
N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488); N-Ac-O-dodecyl-serine chloromethyl ketone (HI-489); N-Trifluoroacetyl-S-dodecyl-cysteine chloromethyl ketone (HI-490); N-Benzoyl-S-dodecyl-cysteine chloromethyl ketone (HI-491).
The compounds of the invention are capable of forming both pharmaceutically acceptable acid addition and/or base salts. Base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Also included are heavy metal salts such as for example silver, zinc, cobalt, and cerium. Examples of suitable amines are N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamene, N-methylglucamine, and procaine.
Pharmaceutically acceptable acid addition salts are formed with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, suliuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, gluconic, fumaric, succinic, ascorbic, maleic, methanesulfonic, and the like. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce either a mono or di, etc. salt in the conventional manner. The free base forms may be regenerated by treating the salt form with a base. For example, dilute solutions of aqueous base may be utilized. Dilute aqueous sodium hydroxide, potassium carbonate, ammonia, and sodium bicarbonate solutions are suitable for this purpose. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for the purposes of the invention.
Cytotoxic Compounds
The compounds of the invention are effective cytotoxic agents, for example, against tumor cells such as leukemic and breast cancer cells. In the methods of the invention, the cytotoxic effects of alkyl ketone compounds are achieved by contacting cells, such as tumor cells, with micromolar amounts of the inhibitory compound. By way of example, a particularly useful anti-tumor agent is N- Ac-S- dodecy 1-Cys chloromethyl ketone (HI-131) as shown in the Examples below. Tumor Treatment
The compounds of the invention can be used in methods of tumor treatment, for example, by administering to a subject a compound of the invention in order to achieve an inhibition of tumor cell growth, a killing of tumor cells, induction of apoptosis, and/or increased patient survival time.
The cytotoxic compounds of the invention are suitable for use in mammals. As used herein, "mammals" means any class of higher vertebrates that nourish their young with milk secreted by mammary glands, including, for example, humans, rabbits, and monkeys.
Apoptosis
Apoptosis, or programmed cellular death, is an active process requiring new protein synthesis. Typically, the process requires ATP, involves new RNA and protein synthesis, and culminates in the activation of endogenous endonucleases that degrade the DNA of the cell, thereby destroying the genetic template required for cellular homeostasis. Apoptosis is observed in controlled deletion of cells during metamorphosis, differentiation, and general cell turnover and appears normally to be regulated by receptor-coupled events. For these reasons, apoptosis has been called "programmed cell death" or "cell suicide." While every cell likely has the genetic program to commit suicide, it is usually suppressed. Under normal circumstances, only those cells no longer required by the organism activate this self-destruction program.
Apoptotic cell death is characterized by plasma membrane blebbing, cell volume loss, nuclear condensation, and endonucleolytic degradation of DNA at nucleosome intervals. Loss of plasma membrane integrity is a relatively late event in apoptosis, unlike the form of cell death termed necrosis, which can be caused by hypoxia and exposure to certain toxins and which is typically characterized, early-on by increased membrane permeability and cell rupture. As demonstrated in the Examples, the alkyl ketone compounds of the invention are effective agents for inducing apoptosis in tumor cells.
Administration Methods
The compounds of the present invention can be formulated as pharmaceutical compositions and administered to a mammalian host, including a human patient, in a variety of forms adapted to the chosen route of administration. The compounds are preferably administered in combination with a pharmaceutically acceptable carrier, and may be combined with or conjugated to specific delivery agents, including targeting antibodies and/or cytokines. The compounds can be administered by known techniques, such as orally, parentally (including subcutaneous injection, intravenous, intramuscular, intrasternal or infusion techniques), by inhalation spray, topically, by absorption through a mucous membrane, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants or vehicles. Pharmaceutical compositions of the invention can be in the form of suspensions or tablets suitable for oral administration, nasal sprays, creams, sterile injectable preparations, such as sterile injectable aqueous or oleagenous suspensions or suppositories.
For oral administration as a suspension, the compositions can be prepared according to techniques well-known in the art of pharmaceutical formulation. The compositions can contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents. As immediate release tablets, the compositions can contain microcrystalline cellulose, starch, magnesium stearate and lactose or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
For administration by inhalation or aerosol, the compositions can be prepared according to techniques well-known in the art of pharmaceutical formulation. The compositions can be prepared as solutions in saline, using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons or other solubilizing or dispersing agents known in the art.
For administration as injectable solutions or suspensions, the compositions can be formulated according to techniques well-known in the art, using suitable dispersing or wetting and suspending agents, such as sterile oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
For rectal administration as suppositories, the compositions can be prepared by mixing with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ambient temperatures, but liquefy or dissolve in the rectal cavity to release the drug. Preferred administration routes include orally, parenterally, as well as intravenous, intramuscular or subcutaneous routes.
More preferably, the compounds of the present invention are administered parenterally, i.e., intravenously or intraperitoneally, by infusion or injection. In one embodiment of the invention, the compounds may be administered directly to a tumor by tumor injection; or by systemic delivery by intravenous injection.
Solutions or suspensions of the compounds can be prepared in water, isotonic saline (PBS) and optionally mixed with a nontoxic surfactant. Dispersions may also be prepared in glycerol, liquid polyethylene, glycols, DNA, vegetable oils, triacetin and mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. The pharmaceutical dosage form suitable for injection or infusion use can include sterile, aqueous solutions or dispersions or sterile powders comprising an active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol such as glycerol, propylene glycol, or liquid polyethylene glycols and the like, vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size, in the case of dispersion, or by the use of nontoxic surfactants. The prevention of the action of microorganisms can be accomplished by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be desirable to include isotonic agents, for example, sugars, buffers, or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the inclusion in the composition of agents delaying absorption — for example, aluminum monosterate hydrogels and gelatin. Sterile injectable solutions are prepared by incorporating the conjugates in the required amount in the appropriate solvent with various other ingredients as enumerated above and, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
Conjugation to a Targeting Moiety The compound of the invention can be targeted for specific delivery to the cells to be treated by conjugation of the compounds to a targeting moiety. Targeting moiety useful for conjugation to the compounds of the invention include antibodies, cytokines, and receptor ligands expressed on the cells to be treated.
The term "conjugate" means a complex formed with two or more compounds.
The phrase "targeting moiety" means a compound which serves to deliver the compound of the invention to a specific site for the desired activity. Targeting moieties include, for example, molecules which specifically bind molecules present on a cell surface. Such targeting moieties useful in the invention include anti-cell surface antigen antibodies. Cytokines, including interleukins, factors such as epidermal growth factor (EGF), and the like, are also specific targeting moieties known to bind cells expressing high levels of their receptors.
Particularly useful targeting moieties for targeting the compounds of the invention to cells for therapeutic activity include those ligands that bind antigens or receptors present on the tumor cells to be treated. For example, antigens present on B-lineage cancer cells, such as CD 19, can be targeted with anti-CD 19 antibodies such as B43. Antibody fragments, including single chain fragments, can also be used. IL4 can also be used to target B-cells. Cancer cells expressing EGF or IGF receptors can be targeted with the binding ligand. Other such ligand-receptor binding pairs are known in the scientific literature for specific cancers. Methods for producing conjugates of the compounds of the invention and the targeting moieties are known.
Useful Dose When used in vivo to kill tumor cells, the administered dose is that effective to have the desired effect, such as sufficient to reduce or eliminate tumors. Appropriate amounts can be determined by those skilled in the art, extrapolating using known methods and relationships, from the in vitro data provided in the Examples. In general, the dose of the novel alkyl ketone compounds effective to achieve tumor cell apoptosis, reduction in tumors, and increased survival time, is 1-100 mg/kg body weight/dose for a direct targeted administration.
The effective dose to be administered will vary with conditions specific to each patient. In general, factors such as the disease burden, tumor location (exposed or remote), host age, metabolism, sickness, prior exposure to drugs, and the like contribute to the expected effectiveness of a drug. One skilled in the art will use standard procedures and patient analysis to calculate the appropriate dose, extrapolating from the data provided in the Examples. In general, a dose which delivers about 1-100 mg/kg body weight is expected to be effective, although more or less may be useful.
In addition, the compositions of the invention may be administered in combination with other anti-tumor therapies. In such combination therapy, the administered dose of the alkyl ketone compounds may be less than for single drug therapy.
EXAMPLES
The invention may be further clarified by reference to the following
Examples, which serve to exemplify some of the embodiments, and not to limit the invention in any way.
Example 1
Synthetic procedure for Alkyl Ketones The methods used to synthesize the alkyl ketone compounds beginning from readily available starting materials and ending with the desired compounds are described below.
The compounds contained within Table 1, Table 2, Table 3, and Table 6 were synthesized according to Schemes 1, 2, 3, and 4 illustrated below. In each scheme, a single compound is exemplified and used as a model to generally describe the synthesis. The specific synthesis of the other compounds is then discussed in detail.
The pathway used to synthesize the remaining compounds contained within
Tables 3 and 6 and the compounds in Tables 4 and 5 are also described in detail below. All chemicals were purchased from Aldrich Chemical Company (Milwaukee, Wisconsin) and used directly for synthesis without further purification. Anhydrous tetrahydrofuran was dried over sodium and distilled immediately prior to use. Column chromatography was performed using 230-400 mesh silica gel obtained from the Merck Company, with eluant as noted in the experimental procedure.
COMPOUNDS SYNTHESIZED ACCORDING TO SCHEME 1
The compounds (3a-e and 4a-e in Table 1; 3f, 4f, 3g, and 4g in Table 2) were prepared by the pathway exemplified in Scheme 1 for N-Ac-S-farnesyl-Cys chloromethyl ketone (HI-368) (4a).
Scheme 1
Figure imgf000017_0001
2a
l
Figure imgf000017_0002
3a 4a
General description of the synthetic pathway illustrated in Scheme 1
The first step of scheme 1 was isoprenylation of the thiol group of N~Ac- Cys-OH by reaction of the appropriate isoprenyl bromide in a 4 M solution of ammonia in methanol according to the method of Brown and co-workers. This step was carried out in the presence of ethyl acetate when N-Ac-Cys-OH was dodecylated in order to solvate the bromododecane. In the second step, the S- alkylated acid (2a) was activated as the mixed anhydride derivative using isobutylchloroformate and converted to the diazomethyl ketone (3 a) by treatment with diazomethane. In the last step, the diazomethane was converted to the chloromethyl ketone (4a) with HCI in ethyl acetate at 0 °C for 10 minutes. The chloromethyl compounds in Tables 1 and 2, 4a-4g, were made from the analogous diazomethyl compounds, 3a-3g, by replacement of the diazomethyl group with a chloromethyl group. The specific synthesis of each two member analogous group will therefore be considered together.
Specific methods used to synthesize the analogous pain of diazomethyl compounds using Scheme 1
1. N-Ac-S-trα«5-tr «s-farnesyl-Cys diazomethyl ketone (HI-367)(3a) and
N-AcS-trans-trans- farnesyl-Cys chloromethyl ketone (HI-368)(4a)
Trans-trans -farnesyl bromide (1.57 g, 1.49 mL, 5.5 mmol) was added to
N-Ac-Cys-OH (1) (0.82 g, 5 mmol) in 4 M ammonia in methanol (35 mL) at 0 °C. The reaction was stirred at 0 °C for 3 h then at room temperature for 1 h. The solvent was removed under reduced pressure and the residue partitioned between 1- butanol and water. The butanol layer was dried (MgSO4) and the solvent removed under reduced pressure. The residue was redissolved in methanol and washed with hexane. The methanol was then removed under reduced pressure to give N-Ac-S- trans- traws-farnesyl-Cys-OH (2a).
The N-Ac-S-rrarø-/rα«s-farnesyl-Cys-OH (2a) (1.84 g, 5 mmol) produced in the previous step was dissolved in dry THF (30 mL) and cooled to - 15 °C. 4-methyl morpholine (0.51 g, 0.55 mL, 5 mmol) and z'so-butyl chloroformate (0.68 g, 0.65 mL, 5 mmol) were added to the solution. The mixture was stirred at -15 °C for 5 minutes before being filtered by gravity into a solution of diazomethane in ethanolic ether (11 mmol, 30 mL) cooled in an ice bath. The resulting solution was stirred in ice for 3 h. Excess diazomethane was purged with nitrogen gas and the reaction mixture was washed with 5% sodium bicarbonate solution and water, dried over MgSO4 , and then the solvent was removed under reduced pressure. The product was purified by chromatography on silica gel (10- 50% ethyl acetate in hexane) to give N-Ac-S-trαns-trαns-farnesyl-Cys diazomethyl ketone (3a). A solution of HCI in ethyl acetate (1 M, 2 mL, 2 mmol) was added to a solution of the previously synthesized N-Ac-S-frαHs-fr ra'-farnesy 1-Cys diazomethyl ketone (3a) (1.57 g, 1 mmol) in ethyl acetate (10 mL) cooled in an ice bath. The reaction mixture was stirred at 0 °C for 5 to 10 min until the starting material was consumed by TLC. The solvent was then removed under reduced pressure and the residue purified by chromatography on silica gel (1 :3 ethyl acetate :hexane) to give N~Ac-S-tπm.s-trα/w-farnesyl-Cys chloromethyl ketone (4a).
2. N-Ac-S-tr ns-geranyl-Cys diazomethyl ketone (HI-122)(3c) and
N-Ac-S-trα/w-geranyl-Cys chloromethyl ketone (HI-127)(4c)
N-Ac-S- rα«s-geranyl-Cys-OH (2c) was prepared as described above for N-Ac-S-tttms-frOra-farnesyl-Cys-OH (2a) except that trans-geranyl bromide was used instead of farnesyl bromide.
N-Ac-S-fr-α —geranyl-Cys diazomethyl ketone (HI 122) (3c) was prepared as described above for N-AcS-trαns-trαns-famesy 1-Cys diazomethyl ketone (3 a) except that N-Ac-S-/rαrø-geranyl-Cys-OH (2c) (2.99 g, 10 mmol) was used instead of N-Ac-S-fr"α«s-/rørø-farnesyl-Cys-OH (2a). The crude material produced was purified by chromatography on silica gel (0-67% ethyl acetate in hexane) to give N-Ac-S-trø/w-geranyl-Cys diazomethyl ketone (HI 122) (3c).
N-Ac-S-fr-αrø— geranyl-Cys chloromethyl ketone (HI 127) (4c) was prepared as described above for N-Ac-S-trαns- trαns-famesy\-Cys chloromethyl ketone (4a) except that N-Ac-S-fr-αrø-geranyl-Cys diazomethyl ketone (3c) (0.10 g, 0.3 mmol) was used instead of ~N- AcS-tr αns- trans- famesy 1-Cys diazomethyl ketone (3a). The crude material produced was purified by chromatography on silica gel (0-40% ethyl acetate in hexane) to give N-Ac-S-trαns-geranyl-Cys chloromethyl ketone (HI 127) (4c).
3. N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (HI-123)(3d) and
N-Ac-S-(3-methyl-2-butenyl)-Cys chloromethyl ketone (HI-128)(4d)
N-Ac-S-(3-methyl-2-butenyl)-Cys-OH (2d) was prepared as described above for N-Ac-S-trα s—frøTM-farnesyl-Cys-OH (2a) except that 4-bromo-2- methyl-2-butene was used instead of farnesyl bromide.
N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (3d) was prepared as described above for N-Ac-S-trαns-trαns-famesy\-Cys diazomethyl ketone (3a) except that N-Ac-S-(3-methyl-2-butenyl)-Cys-OH (2d) (0.69 g, 3 mmol) was used instead of N-AcS-trans- trans- farnesyl-Cys-OH (2a). The crude material was purified by chromatography on silica gel (0-5% methanol in methylene chloride) to give N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (3d). N-Ac-S-(3-methyl-2-butenyl)-Cys chloromethyl ketone (4d) was prepared as described above for ~N-Ac-S-trans-trans-farnesy\-Cys chloromethyl ketone (4a) except that N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (3d) (0.30 g, 1.2 mmol) was used instead of N-Ac-S-trøfls-trøra-farnesyl-Cys diazomethyl ketone (3a). The crude product was purified by chromatography on silica gel (0-50% ethyl acetate in hexane) to give N-Ac-S-(3-methyl-2- butenyl)-Cys chloromethyl ketone (4d).
4. N-Ac-S-dodecyl-Cys diazomethyl ketone (HI-348) (3e) and
N-Ac-S-dodecyl-Cys chloromethyl ketone (HI-131) (4e)
N-Ac-Cys-OH (1.62 g, 9.9 mmol) and bromododecane (2.5 g, 10 mmol) were dissolved in a mixture of ethyl acetate (30 mL) and methanol (20 mL). A solution of NH3 (4.2 M, 100 mL) in methanol was added at 0 °C and the reaction mixture was allowed to stir overnight at room temperature. The solvent was then removed under reduced pressure and the residue was partitioned between ethyl acetate and 1 M HCI. The organic layer was dried over MgSO and the solvent removed under reduced pressure to give N-Ac-S-dodecyl-Cys-OH (2e).
N-Ac-S-dodecyl-Cys diazomethyl ketone (3e) was prepared as described above for N-AcS-trans- trans-famesy 1-Cys diazomethyl ketone (3a) except that N-Ac-S-dodecyl-Cys-OH (2e) (0.96 g, 2.9 mmol) was used instead ofN-Ac-S- trans- trans-famesyl-Cys-OH (2a). The crude product was purified by chromatography on silica gel (1 :3 ethyl acetate/hexane) to give N-Ac-S-dodecyl- Cys diazomethyl ketone (3e).
N-Ac-S-dodecyl-Cys chloromethyl ketone (4e) was prepared as described above for N-Ac-S-farnesyl-Cys chloromethyl ketone (4a) except that N-Ac-S- dodecyl-Cys diazomethyl ketone (3e) (0.19 g, 0.5 mmol) was used instead of N- Ac-S-trαns- trαns-famesy 1-Cys diazomethyl ketone (3a). N-Ac-S-dodecyl-Cys chloromethyl ketone (4e) was obtained after removal of solvent. 5. N-Boc-S-farnesyl-Cys diazomethyl ketone (HI-82) (3b) and N-Boc-S-farnesyl-Cys chloromethyl ketone (HI-124) (4b)
These compounds were prepared using published literature procedures starting from L-cysteine.
6. S-frαHS-trα/ts-Farnesyl-mercaptoethyl diazomethyl ketone (HI 83) (3f) and
S-i,rαns-/rαn.s-Farnesy--2-mercaptoethyl chloromethyl ketone (HI 125)
(4f) 3-(S-trørø-?r ra-Farnesyl)-mercaptopropionic acid (2f) was prepared as described above for N-Ac-S-frαra— rα — farnesyl-Cys-OH (2a) except that 3- mercaptopropionic acid was used instead of N-Ac-Cys-OH (1).
S-trørø-^rørø-Farnesyl-mercaptoethyl diazomethyl ketone (3f) was prepared as described above for N-AcS-trans-trans-famesy 1-Cys diazomethyl ketone (3a) except that 3-(S-trαns- trans- Farnesyl)-mercaptopropionic acid (2f) was used instead of N-Ac-S-t w- tr ans-famesyl-Cys-OH (2a). The crude material was purified by chromatography on silica gel (1% MeOH in CHC13) to give S-trα«5-trα«5-Farnesyl-mercaptoethyl diazomethyl ketone (3f).
S-trαra-?røtts-Farnesyl-2-mercaptoethyl chloromethyl ketone (HI 125) (4f) was prepared as described above for N-Ac-S-trαns- π s—farnesyl-Cys chloromethyl ketone (4a) except that S-frøns-tr ra'-Farnesyl-mercaptoethyl diazomethyl ketone (3f) (0.52 g, 1.6 mmol) was used instead of N-Ac-S-trø/w- fr-αtts-farnesyl-Cys diazomethyl ketone (3a). The crude product was purified by chromatography on silica gel (0-10% ether in hexane) to give S-trαns-trαns- Farnesyl-2-mercaptoethyl chloromethyl ketone (HI 125) (4f).
7. S-frα«s-trα«s-Farnesyl-mercaptomethyI diazomethyl ketone (HI 84) (3g) and
S-frαits-frα/w-Farnesyl-mercaptomethyl chloromethyl ketone (HI 126) (4g)
S-trα '-frΥWs-Farnesyl-mercaptoacetic acid (2g) was prepared as described above for N-Ac-S-fr-αra—fr-α —farnesyl-Cys-OH (2a) except that mercaptoacetic acid was used instead of N-Ac-Cys-OH (1).
S-tr ra-?rα/75—Farnesyl-mercaptomethyl diazomethyl ketone (3g) was prepared as described above for N-Ac-S-trαns- trans- famesy 1-Cys diazomethyl ketone (3a) except that S- rarø-^rαra-Farnesyl-mercaptoacetic acid (2g) (0.71 g, 2.4 mmol) was used instead of N-Ac-S-frøra,-fr"<ms,-farnesyl-Cys-OH (2a). The crude material was purified by chromatography on silica gel (0-100% CHC13 in hexane) to give S-trαn.s-t/'αn.s-Farnesyl-mercaptomethyl diazomethyl ketone
(3g). S-tra -frø -Farnesyl-mercaptomethyl chloromethyl ketone (4g) was prepared as described above for N-AcS-trans- trans- farnesyl-Cys chloromethyl ketone (4a) except that S-trans- frαrø-Farnesyl-mercaptomethyl diazomethyl ketone (3g) (0.58 g, 1.8 mmol) was used instead of N-Ac-S-trøws-trα '-farnesyl- Cys diazomethyl ketone (3a). The crude product was purified by chromatography on silica gel (0-10% ether in hexane) to give S-trα/is-trα/w-Farnesyl- mercaptomethyl chloromethyl ketone (4g).
COMPOUNDS SYNTHESIZED ACCORDING TO SCHEME 2
The synthesis of compounds 8 and 9 in Table 1 were prepared by the pathway exemplified in Scheme 2.
Scheme 2
DodecylBr NH3, MeOH, EtOAc
Figure imgf000022_0002
Figure imgf000022_0001
5 6 7
HCI
Figure imgf000022_0003
Figure imgf000022_0004
General description of the synthetic pathway illustrated in Scheme 2
The first step in scheme 2 was the dodecylation of cysteine methyl ester in a mixture of ethyl acetate and methanol. This was followed by Boc-protection, ester hydrolysis and conversion in turn to the chloromethyl ketone (8). S-Dodecyl-Cys chloromethyl ketone hydrochloride (9) was prepared from N-Boc-S-dodecyl-Cys chloromethyl ketone (8), by simply deprotecting the Boc group in a saturated solution of HCI in ethyl acetate.
Specific methods used to synthesize compounds using Scheme 2
8. N-Boc-S-dodecyl-Cys chloromethyl ketone (HI-129) (8) and
S-Dodecyl-Cys chloromethyl ketone hydrochloride (HI-252) (9)
Ethyl acetate (30 mL) was added to a mixture of Cys-OCH3 hydrochloride
(1.71 g, 10 mmol) and bromododecane (2.5 g, 10 mmol) followed by addition of a solution of NH3 (6.4 M) in methanol. The resulting cloudy suspension was allowed to stir overnight at room temperature and then the insoluble material was filtered off. The solution was concentrated and ethyl acetate (100 mL) was added. The solution was subsequently washed with water (3 x 40 mL) and dried over Na2SO4 to obtain S-Dodecyl-Cys-OCH3 (6). Di-te/ -butyl dicarbonate (1.7 mL, 7.4 mmol) was added to a solution of the previously synthesized S-dodecyl-Cys-OCIL (6) (2.11 g, 7 mmol) in ethyl acetate at 0 °C . The reaction mixture was allowed to stir for 4 h at room temperature. N-
Boc-S-dodecyl-Cys-OCH3 was obtained after removal of solvent.
A solution of NaOH (3 M, 3.6 mL, 10.8 mmol) was added to a solution of N-Boc-S-dodecyl-Cys-OCH3 (3.42 g, 8.5 mmol) in methanol (80 mL) at 0 °C.
The reaction mixture was allowed to stir overnight at room temperature and then the solvent was removed under reduced pressure. Water (50 mL) was added to the residue and the aqueous solution, whose pH value was adjusted to 5, was washed with hexane (2 x 30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined ethyl acetate fractions were dried over anhydrous Na2SO and the solvent removed under reduced pressure to give N-Boc-S-dodecyl-Cys-OH (7).
N-Boc-S-dodecyl-Cys diazomethyl ketone was prepared as described above for N-AcS-trans- trans-famesy 1-Cys diazomethyl ketone (3 a) except that N-Boc-S-dodecyl-Cys-OH (7) (0.89 g, 2.3 mmol) was used instead of N-Ac-S- trans- trans- farnesyl-Cys-OH (2a). The crude product was purified by chromatography on silica gel (1:2 ethyl acetate/hexane) to give N-Boc-S-dodecyl-
Cys diazomethyl ketone.
N-Boc-S-dodecyl-Cys chloromethyl ketone (8) was prepared as described above for N-Ac-S-trαrø-fr-αrø—farnesyl-Cys chloromethyl ketone (4a) except that N-Boc-S-dodecyl-Cys diazomethyl ketone (0.56 g, 1.4 mmol) was used instead of N-Ac-S-trø ,-fr*α — farnesyl-Cys diazomethyl ketone (3a). N-Boc-S-dodecyl- Cys chloromethyl ketone (8) was obtained upon removal of solvent.
The N-Boc-protected chloromethyl ketone (8) (0.21 g, 0.5 mmol) was dissolved in ethyl acetate (20 mL) and cooled in an ice bath. It was then saturated with dry HCI gas and the solution was stirred at room temperature until the starting material had disappeared by TLC (approx. 2 h). The solvent was removed under reduced pressure and the product, S-Dodecyl-Cys chloromethyl ketone hydrochloride (9), was obtained after recrystallization from ether.
COMPOUNDS SYNTHESIZED ACCORDING TO SCHEME 3
The compounds 12 and 13 in Table 1 were prepared by the pathway exemplified in Scheme 3.
Scheme 3
Figure imgf000025_0001
10 11
l
Figure imgf000025_0002
12 13
General description of the synthetic pathway illustrated in Scheme 3
The first step in scheme 3 was the farnesylation of cysteine methyl ester according to the method of Brown et al. The farnesylated cysteine methyl ester was then coupled with N-Boc-Gly-OH using EDC/HOBt. The ester was hydrolyzed to the acid (11) and the chloromethyl ketone prepared via the diazomethyl ketone (12).
Specific methods used to synthesize compounds using Scheme 3
9. N-Boc-Gly-S-trα/w-tr MS-farnesyl-Cys diazomethyl ketone (HI-401)
(12) and N-Boc-Gly-S-trα/w-tr ns-farnesyl-Cys chloromethyl ketone (HI-130)
(13)
A solution of ammonia (3.4 M, 80 mL) in methanol was added to a mixture of Cys-OCH3 hydrochloride (1.72 g, 10 mmol) and trans- trans-famesyl bromide (2.85 g, 10 mmol) in methanol (30 mL) at 0 °C. The reaction mixture was allowed to stir overnight at room temperature and then the solvent was removed under reduced pressure. The remaining residue was dissolved in ethyl acetate (100 mL) which had been washed with HCI (0.3 M), water, NaHCO3 (6%) and dried over Na SO4. The solvent was then removed under reduced pressure to give S-trαns- rrø>w-Farnesyl-Cys-OCH3 (10).
DMF (30 mL) was added to a mixture of N-Boc-Gly-OH (1.3 g, 7.5 mmol), S-/røra-frαrø-Farnesyl-Cys-OCH3 (10) (1.28 g, 7.5 mmol) and HOBt (0.6 g, 4.4 mmol). The solution was cooled to 0 °C before the addition of EDC (1.52 g, 8.2 mmol) and the reaction mixture was stirred overnight at room temperature. The solvent was then removed under reduced pressure. The resulting residue was dissolved in ethyl acetate (60 mL) which had been washed with HCI (0.2 M), water, NaHCO3 (6%) and dried over Na2SO4. Removal of the solvent under reduced pressure gave a yellow oil that was purified via chromatography on silica gel (1 : 1 ethyl acetate/hexane) to give pure N-Boc-Gly-S-trø ,-fr*α ,-farnesyl-Cys-OCH
N-Boc-Gly-S- rαrø-^rara-farnesyl-Cys-OCH (1.25 g, 2.52 mmol) was dissolved in methanol (70 mL) and then a solution of NaOH (3 M, 2.5 mL, 7.56 mmol) at 0 °C was added. The solution was stirred overnight at the same temperature. The solvent was then removed and the residue was dissolved in water (50 mL) that was subsequently acidified to pH 5. The aqueous solution was extracted with chloroform, the combined organic fractions were dried over anhydrous Na2SO , and the solvent was removed under reduced pressure to give N- Boc-Gly-S-tπ s-trαrø-farnesyl Cys-OH (11).
N-Boc-Gly-S-fr-flra—trύra-farnesy 1-Cys diazomethyl ketone (12) was prepared as described above for N- Ac-S-tr ans- trans- famesy 1-Cys chloromethyl ketone (4a) except that N-Boc-Gly-S-^απs-frara'-farnesyl-Cys-OH (11) (0.39 g, 0.8 mmol) was used instead of N-AcS-trαns-trαns-farnesy\-Cys diazomethyl ketone (3a). The crude material was purified by chromatography on silica gel (1 :3 ethyl acetate/hexane) to give N-Boc-Gly-S-trαns- frαns-farnesyl-Cys diazomethyl ketone (12). N-Boc-Gly-S- r ra- frøra-farnesyl-Cys chloromethyl ketone (13) was prepared as described above for N-Ac-S-trα —trα«s-farnesy 1-Cys chloromethyl ketone (4a) except that N-Boc-Gly-S-frαrø-tra/75-farnesy 1-Cys diazomethyl ketone (0.21 g, 0.41 mmol) was used instead of Η-Ac-S-trαns- rαns-fa esyl-Cys diazomethyl ketone (3 a). N-Boc-Gly-S-trα/w-trα/is-farnesyl-Cys chloromethyl ketone (13) was obtained upon removal of solvent. COMPOUNDS SYNTHESIZED ACCORDING TO SCHEME 4
The compounds 4h-4y in Table 3 and the compounds in Table 6 were prepared by the pathway exemplified in Scheme 4.
Scheme 4
Figure imgf000027_0001
2h-y 4h-y
Synthesis of the straight chain alkyl ketone derivatives (Tables 3 and 6)
The straight chain alkyl ketone derivatives (4h-y) were synthesized by a modification of the standard literature procedure. Previously, the standard conditions for making diazomethyl ketones were used, but a closer study of the dodecyl derivative, N-Ac-S-dodecyl-Cys chloromethyl ketone (4e), showed significant formation of the methyl ester as a side-product. Presumably, the mixed anhydride intermediate either could not completely form or was hydrolyzed back to the acid before the diazomethane could react with it. Conducting the mixed anhydride formation at -78 °C increased the stability and longevity of the mixed anhydride and improved yield. Adding diazomethane directly to the solution at - 78 °C without filtration led to over a three-fold improvement in yield from 15 to 55% for the dodecyl derivative, N-Ac-S-dodecyl-Cys chloromethyl ketone (4e), and gave a satisfactory yield of product for the majority of cysteine derivatives reported herein.
10. Specific methods used to synthesize the compounds of Table 3 and Table 6
The appropriate 1-bromoalkane (11 mmol) was added to a solution of N- Ac-Cys-OH (1.63 g, 10 mmol) in methanol (15 mL) and ethyl acetate (15 mL) that had been cooled in an ice bath. This was followed by the addition of a solution of ammonia in methanol (4M, 50 mL). The resulting solution was allowed to slowly warm to room temperature and was stirred overnight. The solvent was then removed under reduced pressure and the residue partitioned between ethyl acetate and 1M HCI. The layers were separated and the organic layer was dried over anhydrous MgSO4. The solvent was removed under reduced pressure to give the desired N- Ac-S-alkyl-cysteine compound. An analytical sample of this could be obtained by recrystallization from ethyl acetate/hexane but was otherwise of sufficient purity to be used in further reactions.
NMM (0.20 g, 0.22 mL, 2 mmol) and isobutyl chloroformate (0.27 g, 0.26 mL, 2 mmol) was added to the desired N-Ac-S-alkyl-cysteine (2 mmol) in anhydrous THF (20 mL) that had been cooled to -78 °C. The solution was then stirred at -78 °C for 20 min. A solution of diazomethane in ethanolic ether (10 mL) was carefully added and the solution allowed to slowly warm to room temperature. Further portions of diazomethane solution were added until a yellow color persisted. The solution was diluted with ether, washed with water and sodium bicarbonate solution and then dried over anhydrous MgSO . The solvent was removed under reduced pressure to yield the crude diazomethyl ketone compound. The diazomethyl ketone was dissolved in ethyl acetate (20 mL) and cooled in an ice bath. A solution of HCI in ethyl acetate (2M, 2 mL) was added and the solution stirred in ice for 5 min until no more diazomethyl ketone could be observed by TLC. The solvent was removed under reduced pressure and the residue purified by chromatography on silica gel (ethyl acetate/hexane) to give the pure chloromethyl ketone compounds in Table 3 and Table 6.
11. Synthesis of the alkyl ketone compounds in Table 4
Synthesis of the compounds having variable R1 groups shown in Table 4 was either by the method described above for HI-131, 348,and 208 or as follows. The bromomethyl ketone (HI-488) was synthesised from the diazomethyl ketone using HBr in a similar fashion to the chloromethyl ketone. The benzoyloxymethyl ketone (HI-508) was made starting from either the bromomethyl ketone or the chloromethyl ketone by displacement of the halogen with benzoic acid in the presence of potassium fluoride in DMF. The aldehyde (HI-274) was made from the acid (HI- 208, 2e) via formation of the Weinreb amide (HI-267) by activation of the acid as its' mixed anhydride followed by coupling with N,O-dimethylhydroxylamine. The aldehyde was then synthesized by reduction of the Weinreb amide using LiAlFL. The thiomethyl ketones (HI-269, 302, 399, 365 & 273) were made by displacement of the halogen of the bromo or chloromethyl ketones with the appropriate thiol in the presence of potassium carbonate in DMF.
12. Synthesis of the alkyl ketone compounds in Table 5 The compounds varying the R4 substituent (Table 5) were made either as noted above for HI-252, 131, and 129 or as follows. The majority of these compounds were made by reacting the appropriate acyl chloride or anhydride with the free amine compound (HI-252) in the presence of triethylamine. The dimethylaminobenzoyl derivative (HI-268) required activation of dimethylaminobenzoic acid as its mixed anhydride prior to reaction with the free amine. The serine derivative (HI-266) was synthesized by reaction of Boc-Ser-OH with sodium hydride and 1-bromododecane in DMF to give the N-Boc-O- dodecyl-Ser-OH and then with isobutylchloroformate/diazomethane and HCI in ethyl acetate at 0 °C as in the chemistry noted above. The acetyl serine derivative (HI-489) was synthesized from HI-266 by removal of the Boc group in saturated HCI in ethyl acetate followed by acetylation using acetic anhydride in dichloromethane in the presence of triethylamine.
Example 2
Characterization of synthesized compounds
NMR spectra were recorded using a 300 MHz Varian instrument and the chemical shifts reported are in ppm based on tetramethylsilane as the internal standard. Chemical shifts for 13C NMR are referenced to the chloroform peak at 77.0 ppm. Melting points were done using a Fisher-Jones apparatus and are uncorrected. Fourier Transform Infra-red spectra were recorded on a FT-Nicolet model Protege 460 instrument. GC/MS analysis was done using a Hewlett-Packard GC/MS model 6890 with an HP5973 electron impact mass spectrometer. In addition, a Hewlett-Packard Matrix- Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) spectrometer model G2030A was used with cyano hydroxy benzoic acid as the matrix. Data are shown below. N-Ac-S-frαns-t/-α/tt-farnesyl-Cys-OH (2a) Yellow oil. Yield 99%, 1.83 grams. 1H NMR (DMSO-d6) δ 1.54 (s, 6H), 1.61 (s, 3H), 1.62 (s, 3H), 1.84 (s, 3H), 1.97 (m, 8H), 2.60 (dd, J = 8.5, 13.7 Hz, IH), 2.79 (dd, J = 5.0, 13.7 Hz, IH), 3.13 (m, 2H), 4.35 (m, IH), 5.05 (m, 2H), 5.14 (t, J = 7.8 Hz, IH), 8.22 (d, J = 8.2 Hz, IH); 13C NMR (CDC13) δ 172.5, 169.5, 138.7, 134.8, 130.9, 124.3, 123.8, 120.4, 52.1, 48.8, 32.2, 29.0, 26.4, 26.1, 25.8, 22.6, 17.8, 16.1, 16.0; IR (KBr) 3334, 2966, 2922, 2854, 1732, 1659, 1543, 1441, 1377, 1219 cm"1.
N-Ac-S- αns-geranyl-Cys-OH (2c) Clear oil. Yield 97%, 2.92 g. Η
NMR (CDC13) δ 1.60 (s, 3H), 1.65 (s, 3H), 1.68 (s, 3H), 2.07 (m, 4H), 2.10 (s, 3H), 2.95 (ABX, J - 3.6, 5.7, 13.2 Hz, 2H), 3.18 (d, J = 6.9 Hz, 2H), 4.72 (m, IH), 5.07 (m, IH), 5.20 (t, J= 7.9 Hz, IH), 6.72 (br, IH), 9.95 (br, IH); I3C NMR (CDC13) δ 177.1, 139.9, 131.6, 123.7, 119.4, 52.6, 39.7, 33.0, 30.1, 29.8, 26.5, 25.8, 23.0, 20.9, 17.8, 16.2; IR (KBr) 3307, 2968, 2857, 2611, 1716, 1646, 1550, 1417, 1377, 1241 cm"1; MS (MALDI-TOF) 323 (M + H + Na).
N-Ac-S-(3-methyl-2-butenyI)-Cys-OH (2d) Clear viscous oil. Yield 83%, 0.96 g.1H NMR (CDC13) δ 1.66 (s, 3H), 1.73 (s, 3H), 2.07 (s, 3H), 2.95 (ABX,
J= 4.6, 6.2, 13.9 Hz, 2H), 3.17 (d, J- 7.7 Hz, 2H), 4.65 (m, IH), 5.20 (t, J= 7.9 Hz,
IH), 7.28 (br, IH), 8.25 (br, IH); 13C NMR (CDC13) δ 174.1, 171.2, 136.1, 119.7,
52.7, 33.1, 30.1, 25.9, 25.8, 22.9, 17.8; IR (KBr) 3271, 3078, 2966, 2930, 2874, 1722, 1651, 1615, 1557, 1427, 1377, 1299, 1213, 1107, 1031 cm-1.
N-Ac-S-dodecyl-Cys-OH (2e) White solid. Yield 98%, 3.23 g. m.p. 82- 84 °C. 1H NMR (CDC13) δ 0.88 (t, J= 6.6 Hz, 3H), 1.26 (s, 20H), 1.57 (m, 2H), 2.09 (s, 3H), 2.55 (t, J - 7.4 Hz, 2H), 3.03 (m, 2H), 4.75 (m, IH), 6.40 (d, J = 7.1 Hz, IH); "C NMR (CDC13) δ 168.3, 47.3, 28.8, 28.1, 27.3, 25.0, 24.9, 24.8, 24.6, 24.2, 18.4, 18.1, 9.6; IR (KBr) 3334, 2922, 2850, 1703, 1622, 1562, 1470, 1416, 1377, 1315, 1257, 1244 cm"1; MS (MALDI-TOF) 332.7 (M + 1).
3-(S-tr ns-tr «s-Farnesyl)-mercaptopropionic acid (2f) Clear oil.
Yield 100%, 1.54 g. 1H NMR (CDC13) δ 1.60 (s, 6H), 1.66 (s, 3H), 1.68 (s, 3H), 2.03 (m, 8H), 2.60 (t, J= 6.8 Hz, 2H), 2.72 (t, J= 6.8 Hz, 2H), 3.17 (d, J= 7.7 Hz, 2H),
5.09 (m, 2H), 5.22 (t, J = 7.3 Hz, IH), 8.77 (br, IH); 13C NMR (CDC13) δ 162.9,
139.0, 135.2, 131.2, 124.2, 123.7, 120.0, 60.4, 39.75, 39.65, 36.8, 35.3, 31.7, 29.4,
26.8, 26.5, 26.1, 25.8, 17.8, 16.2, 16.1; IR (KBr) 3179, 2969, 2920, 2855, 1710,
1595, 1436, 1381, 1307 cm -1
S-trαns-frans-Farnesyl-mercaptoacetic acid (2g) Clear oil. Yield 97%,
1.43 g.1H NMR (CDC13) δ 1.60 (s, 6H), 1.66 (s, 3H), 1.68 (s, 3H), 2.03 (m, 8H),
3.19 (s, 2H), 3.30 (d, J= 7.7 Hz, 2H), 5.09 (m, 2H), 5.21 (m, IH), 8.95 (br, IH); 13C
NMR (CDC13) 176.5, 140.7, 135.3, 131.2, 124.2, 123.5, 118.9, 39.7, 39.6, 32.0, 30.0, 26.8, 26.4, 25.8, 17.8, 16.12, 16.09; IR (KBr) 3323, 2959, 2925, 2875, 1705,
1605, 1436, 1381, 1227, 1073, 1033 cm -1 N-Ac-S-trαns-trα w-farnesyl-Cys diazomethyl ketone (HI 367) (3a)
Yellow oil. Yield 51%, 1 g. Η NMR (CDC13) δ 1.60 (s, 6H), 1.67 (s, 3H), 1.68 (s, 3H), 2.03 (m, 8H), 2.05 (s, 3H), 2.82 (ABX, J = 6.3, 6.6, 14.0 Hz, 2H), 3.20 (m, 2H), 4.64 (m, IH), 5.09 (t, J = 6.9 Hz. 2H), 5.22 (t, J = 1.1 Hz, IH), 5.58 (s, IH), 6.51 (d, J = 7.7 Hz, IH); 13C NMR (CDC13) δ 191.8, 169.7, 139.9, 135.3, 131.2, 124.2, 123.6, 119.5, 60.3, 55.2, 54.9, 39.65, 39.55, 33.1, 30.1, 26.7, 26.3, 25.7, 23.1, 17.7, 16.1, 16.0; IR (KBr) 3290, 3057, 2966, 2920, 2854, 2108, 1651, 1533, 1441, 1375 cm"1; GC/MS 363 (M - N2). N-Ac-S-trα/ts-geranyl-Cys diazomethyl ketone (HI 122) (3c) Yellow oil. Yield 45%, 1.45 g. Η NMR (CDC13) δ 1.60 (s, 3H), 1.67 (s, 3H), 1.68 (s, 3H), 2.05 (m, 7H), 2.82 (ABX, J - 6.0, 6.3, 13.8 Hz, 2H), 3.20 (m, 2H), 4.64 (m, IH), 5.08 (m, 2H), 5.22 (t, J = 7.8 Hz, IH), 5.59 (s, IH), 6.56 (d, J = 7.2 Hz, IH); 13C NMR (CDC13) δ 191.8, 169.7, 139.8, 131.6, 123.7, 119.5, 65.8, 55.3, 55.0, 39.6, 33.1, 30.2, 29.7, 26.5, 25.8, 23.2, 17.8, 16.2; GC/MS 295 (M - N2); IR (KBr) 3300, 3061, 2965, 2924, 2856, 2107, 1732, 1651, 1538, 1455, 1373, 1260, 1111 cm l; MS (MALDI-TOF) 296.5 (M + H - N2).
N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (HI 123) (3d) Yellow oil. Yield 50%, 0.38 g. Η NMR (CDC13) δ 1.68 (s, 3H), 1.75 (s, 3H), 2.05 (s, 3H), 2.82 (ABX, J= 6.0, 6.3, 13.5 Hz, 2H), 3.18 (m, 2H), 4.64 (m, IH), 5.21 (m, IH), 5.59 (s, IH), 6.58 (d, J= 7.5 Hz, IH); l3C NMR (CDC13) δ 191.7, 169.6, 136.1, 119.7, 55.3, 54.9, 52.7, 52.6, 51.8, 37.7, 33.2, 30.3, 30.1, 25.7, 25.6, 23.1,
19.1, 17.8; GC/MS 227 (M - N2); IR (KBr) 3296, 3062, 2970, 2928, 2108, 1745, 1667, 1548, 1441, 1373, 1145, 1039 cm"1; MS (MALDI-TOF) 278.6 (M + Na),
256.3 (M + H), 250.4 (M + Na - N2), 228.3 (M + H - N2).
N-Ac-S-dodecyl-Cys diazomethyl ketone (HI 348) (3e) Off-white solid. Yield 15%, 0.16 g. m.p. 45-48 °C. 1H NMR (CDC13) δ 0.88 (t, J= 6.7 Hz, 3H), 1.25 (m, 18H), 1.61 (m, 2H), 2.05 (s, 3H), 2.55 (t, J= 7.4 Hz, 2H), 2.88 (d, J= 6.3 Hz, 2H), 4.62 (m, IH), 5.59 (s, IH), 6.40 (d, J= 7.1 Hz, IH); 13C NMR (CDC13) δ 191.8, 169.8, 55.4, 55.0, 34.1, 32.9, 32.8, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 28.8,
28.2, 23.2, 22.7, 14.14; IR (KBr) 3287, 3068, 2919, 2853, 2126, 1655, 1547, 1383,
1168, 725 cm -1
S-trα/w-trαns-Farnesyl-mercaptoethyl diazomethyl ketone (HI 83) (3f)
Yellow oil. Yield 45%, 0.45 g. 1H NMR (CDC13) δ 1.60 (s, 6H), 1.67 (s, 3H), 1.68 (s, 3H), 2.03 (m, 8H), 2.58 (t, J= 7.2 Hz, 2H), 2.75 (t, J = 7.2 Hz, 2H), 3.17 (d, J = 1.1 Hz, 2H), 5.09 (m, 2H), 5.24 (t, J= 7.3 Hz, IH), 5.29 (s, IH); 13C NMR (CDC13) δ 139.1, 135.2, 131.2, 124.2, 123.6, 120.0, 68.1, 51.8, 39.7, 39.6, 38.7, 34.8, 30.4, 29.8, 29.4, 26.8, 26.5, 26.0, 25.8, 17.8, 16.2, 16.1; IR (KBr) 3095, 2967, 2922, 2855, 2105, 1715, 1645, 1445, 1368, 1318 cm"1; MS (MALDI-TOF) 357 (M + Na).
S— trans-trans- Farnesyl-mercaptomethyl diazomethyl ketone (HI 84) (3g) Yellow oil. Yield 47%. 0.36 g. 1H NMR (CDC13) δ 1.60 (s, 6H), 1.66 (s, 3H), 1.68 (s, 3H), 2.03 (m, 8H), 3.20 (m, 4H), 5.09 (m, 2H), 5.20 (t, J= 7.8 Hz, IH), 5.77 (s, IH); 13C NMR (CDC13) δ 140.6, 135.3, 131.2, 124.2, 123.6, 118.9, 54.1, 47.2, 39.8, 39.7, 38.8, 31.9, 30.0, 39.8, 26.8, 26.6, 26.4, 25.8, 17.8, 16.2, 16.15; IR (KBr) 3107, 2966, 2923, 2854, 2105, 1724, 1639, 1449, 1355 cm"1; MS (MALDI-TOF) 343 (M + Na).
N-Ac-S-trø/ts-trα/w-farnesyr-Cys chloromethyl ketone (HI 368) (4a) Pale yellow solid. Yield 55%, 0.22 grams, m.p. 59-61 °C. Η NMR (CDC13) δ 1.56 (s, 6H), 1.64 (s, 6H), 2.01 (s, 3H), 2.04 (m, 8H), 2.85 (ABX, J = 5.8, 6.6, 13.9 Hz, 2H), 3.14 (m, 2H), 4.31 (s, 2H), 4.85 (m, IH), 5.05 (t, J = 6.9 Hz, 2H), 5.17 (t, J = 7.7 Hz, IH), 6.36 (br, IH); 13C NMR (CDC13) δ 199.9, 170.0, 140.5, 135.4, 131.3, 124.2, 123.5, 119.2, 60.4, 55.3, 47.3, 39.7, 39.6, 31.9, 29.9, 26.7, 26.4, 25.7, 22.9, 17.7, 16.2, 16.0; IR (KBr) 3300, 3061, 2926, 2852, 2825, 1738, 1633, 1541, 1448, 1421, 1371, 1286, 1078 cm"1; GC/MS 363 (M - HCI).
N-Ac-S-trans-geranyl-Cys chloromethyl ketone (HI 127) (4c) Yellow oil. Yield 27%, 0.03 g. Η NMR (CDC13) δ 1.61 (s, 3H), 1.67 (s, 3H), 1.68 (s, 3H), 2.05 (s, 3H), 2.07 (m, 4H), 2.88 (ABX, J= 5.9, 6.3, 13.7 Hz, 2H), 3.18 (m, 2H), 4.34 (m, 2H), 4.89 (q, J= 6.3 Hz, IH), 5.07 (m, IH), 5.21 (t, J- 7.8 Hz, IH); 13C NMR (CDC13) δ 199.8, 169.9, 140.4, 131.8, 123.6, 119.2, 55.3, 47.3, 39.7, 39.6, 32.0, 30.0, 29.8, 26.5, 25.8, 23.0, 17.8, 16.3; IR (KBr) 3342, 2970, 2926, 2859, 1741, 1732, 1664, 1651, 1538, 1446, 1379, 1301, 1084 cm"1; GC/MS 295 (M - CI), 205 (farnesyl).
N-Ac-S-(3-methyl-2-butenyI)-Cys chloromethyl ketone (HI 128) (4d)
Off-white solid. Yield 56%, 0.18 g. 1H NMR (CDC13) δ 1.68 (s, 3H), 1.76 (s, 3H), 2.06 (s, 3H), 2.89 (ABX, J= 6.0, 6.5, 13.8 Hz, 2H), 3.17 (m, 2H), 4.34 (m, 2H), 4.89 (q, J= 6.3 Hz, IH), 5.20 (t, J= 7.8 Hz, IH), 6.32 (d, J= 5.5 Hz, IH); 13C NMR (CDC13) δ 199.8, 169.9, 136.8, 119.4, 55.4, 47.3, 32.1, 30.2, 25.8, 23.0, 17.9; IR (KBr) 3302, 3060, 2976, 2958, 2927, 2853, 1738, 1635, 1541, 1423, 1371, 1286, 1216, 1078 cm"1; GC/MS 227 (M - CI). N-Ac-S-dodecyl-Cys chloromethyl ketone (HI 131) (4e) Pale yellow solid. Yield 100%, 0.18 g. m.p. 73-74 °C. Η NMR (CDC13) δ 0.88 (t, J = 6.7 Hz, 3H), 1.26 (m, 18H), 1.57 (m, 2H), 2.06 (s, 3H), 2.54 (t, J- 7.3 Hz, 2H), 2.94 (ABX, J= 6.0, 6.3, 13.9 Hz, 2H), 4.35 (m, 2H), 4.91 (m, IH), 6.31 (br, IH); 13C NMR (CDC13) δ 195.2, 165.3, 50.8, 42.7, 29.6, 28.4, 28.2, 27.3, 25.1, 25.0, 24.9, 24.83, 24.8, 24.7, 24.5, 24.1, 18.3, 18.1, 9.5; IR (KBr) 3302, 2924, 2854, 1738, 1660,
1537, 1456, 1377, 1261, 1165, 1095, 1040 cm"1; MS (MALDI-TOF), 364.9 (M + 1), 328.9 (M - CI).
S-/r «s-tr /ιs-Farnesyl-2-mercaptoethyl chloromethyl ketone (HI 125) (4f) Yellow oil. Yield 68%, 0.36 g. 1H NMR (CDC13) δ 1.60 (s, 6H), 1.67 (s, 3H), 1.68 (s, 3H), 2.03 (m, 8H), 2.74 (t, J= 6.6 Hz, 2H), 2.89 (t, J= 6.6 Hz, 2H) 3.18 (d, J = 7.5 Hz, 2H), 4.10 (s, 2H), 5.09 (m, 2H), 5.23 (t, J - 7.8 Hz, IH); 13C NMR (CDC13) δ 200.9, 139.2, 135.3, 131.2, 124.2, 123.6, 120.0, 48.3, 40.1, 39.7, 39.6, 29.8, 26.8, 26.5, 25.8, 24.8, 17.8, 16.2, 16.1; IR (KBr) 2964, 2925, 2852, 1726, 1441, 1379, 1351, 1110, 1077 cm"1; GC/MS 342 (M+), 307 (M - CI), 205 (farnesyl); MS (MALDI-TOF) 342.6 (M"). S-trαHS-frαns-Farnesyl-mercaptomethyl chloromethyl ketone (HI 126)
(4 ) Clear oil. Yield 17%, 0.10 g. Η NMR (CDC13) δ 1.60 (s, 6H), 1.66 (s, 3H), 1.68 (s, 3H), 2.03 (m, 8H), 3.16 (d, J = 7.8 Hz, 2H), 3.34 (s, 2H), 4.34 (s, 2H), 5.09 (m, 2H), 5.18 (m, IH); 13C NMR (CDC13) δ 197.2, 140.9, 135.3, 131.1, 124.1, 123.5, 118.6, 46.2, 39.7, 39.6, 38.4, 37.4, 37.1, 32.0, 31.8, 29.8, 26.7, 26.5, 26.3, 25.3, 17.7, 16.2, 16.1; IR (KBr) 3444, 2965, 2926, 2859, 1732, 1712, 1664, 1446, 1384, 1243, 1108 cm"1; GC/MS 328 (M+), 294 (M - CI), 205 (farnesyl).
S-Dodecyl-Cys-OCH3 (6) Light yellow oil. Yield 61%, 1.85 g. Η NMR (CDC13) δ 0.88 (t, J = 6.6 Hz, 3H), 1.26 (s, 20H), 2.53 (t, J - 7.5 Hz, 2H), 2.76 (m, IH), 2.91 (m, IH), 3.67 (m, IH), 3.75 (s, 3H); IR (KBr) 3381, 2924, 2854, 1743, 1466, 1437, 1196, 1175 cm"1; GC/MS 303 (M+).
N-Boc-S-dodecyl-Cys-OCH3 Clear oil. Yield 100%, 2.82 g. Η NMR (CDC13) δ 0.88 (t, J = 7.1 Hz, 3H), 1.25 (s, 20H), 1.45 (s, 9H), 2.51 (t, J = 7.5 Hz, 2H), 2.95 (d, J = 5.2 Hz, IH), 3.76 (s, 3H), 4.52 (m, IH), 5.37 (m, IH); IR (KBr) 2977, 2932, 1814, 1759, 1062 cm"1; GC/MS 403 (M+), 286, 215, 57.
N-Boc-S-dodecyl-Cys-OH (7) Yellow oil. Yield 80%, 2.65 g. Η NMR (CDC13) δ 0.88 (t, J = 6.6 Hz, 3H), 1.24 (m, 20H), 1.45 (s, 9H), 2.52 (t, J = 7.4 Hz,
2H), 2.96 (d, J - 4.9 Hz, 2H), 4.50 (m, IH), 5.38 (br, IH); 13C NMR (CDC13) δ
175.0, 156.0, 80.0, 53.0, 34.5, 34.1, 32.9, 32.6, 32.0, 29.7, 29.6, 29.4, 29.2, 28.8,
28.2, 22.8, 14.0; IR (KBr) 3328, 2922, 2852, 1719, 1503, 1368, 1172, 1052 cm N-Boc-S-dodecyl-Cys diazomethyl ketone Light yellow oil that solidified upon standing. Yield 59%, 0.56 g. Η NMR (CDC13) δ 0.88 (t, J= 6.7 Hz, 3H), 1.26 (s, 18H), 1.46 (s, 9H), 1.58 (m, 2H), 2.53 (m, 2H), 2.89 (m, 2H), 4.30 (m, IH), 5.61 (br, 1H); IR (KBr) 3323, 2924, 2853, 2108, 1718, 1647, 1499, 1369, 1168 cm"1; MS (MALDI-TOF) 386.5 (M - N2).
N-Boc-S-dodecyl-Cys chloromethyl ketone (HI 129 (8) Clear oil that solidified upon standing. Yield 100%, 0.57 g. m.p. 43-49 °C. fH NMR (CDC13) δ 0.88 (m, 3H), 1.26 (s, 18H), 1.45 (s, 9H), 1.57 (m, 2H), 2.53 (m, 2H), 2.93 (m, 2H), 4.37 (s, IH), 4.60 (m, IH), 5.37 (br s, IH); 13C (CDC13) δ 172.5, 130.8, 56.9, 53.2, 52.5, 47.4, 34.5, 33.2, 32.9, 32.8, 32.0, 29.7, 29.6, 29.5, 29.4, 29.2, 28.8, 28.6, 28.3, 28.0 22.8, 14.2; IR (KBr) 3363, 2926, 2854, 1713, 1497, 1468, 1367, 1252, 1167 cm .
S-Dodecyl-Cys chloromethyl ketone hydrochloride (HI 252) (9) Siivery- white solid. Yield 81%, 0.14. m.p. 118-119 °C (decomp.). Η NMR (DMSO-^) δ 0.84 (t, J= 6.7 Hz, 3H), 1.23 (m, 18H), 1.51 (m, 2H), 2.57 (t, J= 7.3 Hz, 2H), 2.96 (dd, J = 6.9, 14.4 Hz, IH), 3.09 (dd, J = 5.8, 14.4 Hz, IH), 4.44 (t, J= 6.2 Hz, IH), 4.84 (m, 2H), 8.58 (br, 3H); 13C NMR (DMSO-d6) δ 193.2, 51.4, 43.9, 27.3, 27.1, 26.2, 24.9, 24.6, 24.4, 24.0, 18.0, 9.8; IR (KBr) 2953, 2922, 2852, 1738, 1470, 1385, 1149 cm"1. S-trα/w-trα/M-Farnesyl-Cys-OCH3 (10) Clear oil. Yield 68%,2.31 g. Η NMR (CDC13) δ 1.59 (s, 6H), 1.67 (s, 6H), 2.08 (m, 8H), 2.68 (dd, J= 7.7, 13.5 Hz, IH), 2.89 (dd, J= 4.8, 13.5 Hz, IH), 3.19 (m, 2H), 3.61 (m, IH), 3.75 (s, 3H), 5.08 (m, 2H), 5.21 (t, J= 7.9 Hz, IH); IR (KBr) 3348, 3376, 3314, 2978, 2922, 2860, 1746, 1684, 1452, 1395, 1209, 1168, 843 cm"1; GC-MS 339 (M+), 270, 202, 135, 81, 69.
N-Boc-Gly-S-trα«s-tra«s-farnesyl-Cys-OCH3 Yellow oil. Yield 61%,
2.27 g. 1H NMR (CDC13) δ 1.45 (s, 9H), 1.60 (s, 6H), 1.66 (s, 3H), 1.68 (s, 3H), 1.94-2.09 (m, 8H), 2.81 (ABX, J = 5.1, 6.2, 13.9 Hz, 2H), 3.16 (m, 2H), 3.76 (s,
3H), 3.85 (t, J= 5.5 Hz, 2H), 4.80 (m, IH), 5.10 (m, 2H), 5.18 (m, 2H), 6.86 (br d, J
= 7.3 Hz, IH); MS (MALDI-TOF), 496.5 (M*).
N-Boc-Gly-S-trans-t/-α/«-farnesyl Cys-OH (11) Clear oil. Yield 61%, 0.74 g. 1H NMR (CDC13) δ 1.45 (s, 9H), 1.60 (s, 6H), 1.65 (s, 6H), 1.95-2.20 (m, 8H), 2.80-3.08 (m, 2H), 3.10-3.27 (m, 2H), 3.70-3.90 (m, 2H), 3.95-4.10 (m, IH), 4.75-4.95 (m, IH), 5.08 (m, 2H), 5.20 (m, IH), 5.41 (s, IH), 7.10 (m, IH); IR (KBr), 3338, 2979, 2930, 1725, 1660, 1525, 1241, 1172 cm"1; MS (MALDI-TOF), 505.3 (M + Na+)
N-Boc-Gly-S-trα«5-trα«s-farnesyl-Cys diazomethyl ketone (HI 401) (12) Yellow oil. Yield 53%, 0.21 g. 1H NMR (CDC13) δ 1.46 (s, 9H), 1.60 (s, 6H), 1.67 (s, 6H), 1.97-2.10 (m, 8H), 2.85 (m, 2H), 3.19 (m, 2H), 3.82 (m, 2H), 4.63 (m, IH), 5.07-5.24 (m, 3H), 5.68 (s, IH), 6.93 (m, IH); 13C NMR (CDC13) δ 169.3, 140.1, 135.4, 131.4, 130.9, 128.8, 124.2, 123.1, 119.4, 80.6, 68.0, 65.9, 55.2, 54.8,
52.8, 48.3, 44.5, 39.7, 33.0, 31.7, 31.0, 30.2, 29.7, 28.3, 26.7, 26.4, 25.7, 23.5, 17.7,
16.2, 16.0; IR (KBr), 3318, 3084, 2983, 2916, 2859, 2105, 1669, 1510, 1369 cm"1.
N-Boc-Gly-S-t/-α«5-trα«5-farnesyl-Cys chloromethyl ketone (HI 130) (13) Yield 100%, 0.22 g. Η NMR (CDC13) δ 1.45 (s, 9H), 1.60 (s, 6H), 1.68 (s, 6H), 1.96-2.09 (m, 8H), 2.81-2.97 (m, 2H), 3.10-3.24 (m, 2H), 3.82 (m, 2H), 4.33 (s, 2H), 4.89 (m, IH), 5.07-5.22 (m, 3H), 6.94 (m, IH); "C NMR (CDC13), δ 199.7, 169.9, 156.0, 140.4, 135.3, 131.2, 124.2, 123.5, 123.1, 119.2, 111.5, 109.7, 80.5,
60.3, 55.4, 53.1, 51.8, 47.4, 44.2, 41.1, 39.6, 39.6, 31.8, 29.9, 28.2, 26.7, 26.4, 25.7, 21.0, 17.7, 16.1, 16.0, 14.1; IR (KBr), 3309, 2987, 2925, 1695, 1514, 1175 cm"1;
MS (MALDI-TOF), 379.4 (M - Boc - CI).
N-Ac-S-methyl-cysteine chloromethyl ketone (4h, HI 314) Yellow oil.
Yield 10%. 1H NMR (CDCI3) δ 2.04 (s, 3H), 2.11 (s, 3H), 2.98 (ABX, J = 6.0, 6.3, 14.0 Hz, 2H), 4.36 (m, 2H), 4.87 (m, IH), 6.41 (br d, IH); 13C NMR (CDCI3) δ 16.1,
22.9, 35.0, 47.4, 55.0, 170.3, 200.0; GC/MS 209 (M+); IR (KBr) 3278, 2922, 1741, 1659, 1537, 1429, 1209 cm"1.
N-Ac-S-ethyl-cysteine chloromethyl ketone (4i, HI 315) Yellow solid. Yield 45%. 1H NMR (CDCI3) δ 1.24 (t, J = 7.4 Hz, 3H), 2.03 (s, 3H), 2.54 (q, J = 7.3 Hz, 2H), 2.93 (ABX, J= 6.0, 6.3, 14.0 Hz, 2H), 4.34 (m, 2H), 4.88 (m, IH), 6.36 (br d, IH); 13C NMR (CDCI3) δ 10.0, 18.3, 22.0, 27.9, 42.7, 50.7, 165.5, 195.4; GC/MS 194 (M-CH2CH3); IR (KBr) 3299, 2927, 2872, 1740, 1659, 1537, 1535, 1425, 1371 cm"1. N-Ac-S-propyl-cysteine chloromethyl ketone (4j, HI 369) Yellow semi- solid. Yield 20%. Η NMR (CDC13) δ 0.96 (t, J= 7.3 Hz, 3H), 1.57 (m, 2H), 2.03 (s, 3H), 2.50 (t, J = 7.3 Hz, 2H), 2.91 (m, 2H), 4.33 (m, 2H), 4.77 (m, IH), 6.32 (br d, IH); 13C NMR (CDCI3) δ 13.2, 22.6, 22.7, 32.5, 34.5, 47.6, 55.5, 170.6, 200.0; GC/MS 238 (M+l) ; IR (KBr) 3020, 2976, 2933, 1740, 1676, 1518, 1423, 1215 cm"
N-Ac-S-butyl-cysteine chloromethyl ketone (4k, HI 363) Yellow solid. Yield 65%. m.p. = 75-76 °C. Η NMR (CDC13) δ 0.90 (t, J= 7.1 Hz, 3H), 1.38 (m, 2H), 1.52 (m, 2H), 2.04 (s, 3H), 2.53 (t, J = 7.3 Hz, 2H), 2.98 (ABX, J = 6.0, 6.3, 14.0 Hz, 2H), 4.28 (m, 2H), 4.93 (m, IH), 6.21 (br d, IH); 13C NMR (CDCI3) δ 14.2, 22.9, 31.4, 32.4, 32.9 47.4, 55.4, 170.1, 200.0; GC/MS 215 (M-HC1); MS (MALDI-TOF) 250 (M* ; IR (KBr) 3425, 3020, 1732, 1651, 1537, 1466 cm"1.
N-Ac-S-pentyl-cysteine chloromethyl ketone (41, HI 224) Yellow solid. Yield 41% yield, m.p. = 74-75 °C. 1H NMR (CDCI3) δ 0.86 (t, J = 6.8 Hz, 3H), 1.2-1.4 (m, 4H), 1.55 (m, 2H), 2.04 (s, 3H), 2.52 (t, J= 7.5 Hz, 2H), 2.93 (ABX, J= 6.0, 6.3, 13.5 Hz, 2H), 4.32 (m, 2H), 4.89 (m, IH), 6.26 (br d, IH); 13C NMR (CDCI3) δ 14.1, 22.7, 22.9, 28.7, 29.2, 29.6, 31.9, 32.9, 47.4, 55.4, 170.1, 200.0; GC/MS 266 (M+l); MS (MALDI-TOF) 266 (M+l); IR (KBr) 3296, 2918, 2850, 1738, 1660, 1539, 1464 cm"1.
N-Ac-S-hexyl-cysteine chloromethyl ketone (4m, HI 357) Yellow solid. Yield 44%. m.p. = 75-77 °C. 1H NMR (CDC13) δ 0.87 (t, J = 6.7 Hz, 3H), 1.2-1.4
(m, 6H), 1.56 (m, 2H), 2.05 (s, 3H), 2.53 (t, J = 7.4 Hz, 2H), 2.93 (ABX, J = 5.8,
6.0, 13.9 Hz, 2H), 4.35 (m, 2H), 4.89 (m, IH), 6.36 (br d, IH); 13C NMR (CDCI3) δ
14.0, 22.5, 22.9, 28.4, 29.4, 29.6, 31.3, 32.8, 47.4, 55.4, 170.1, 200.0; GC/MS 243 (M-HC1); IR (KBr) 3304, 3053, 2951, 2926, 2870, 1738, 1639, 1537, 1425, 1371, 1283 cm"1.
N-Ac-S-heptyl-cysteine chloromethyl ketone (4n, HI 263) Yellow solid.
Yield 19%. m.p. = 77-81 °C. 1H NMR (CDC13) δ 0.87 (t, J = 6.6 Hz, 3H), 1.2-1.4
(m, 8H), 1.54 (m, 2H), 2.03 (s, 3H), 2.51 (t, J = 7.3 Hz, 2H), 2.92 (ABX, J = 5.8, 6.3, 13.7 Hz, 2H), 4.32 (m, 2H), 4.88 (m, IH), 6.25 (br d, IH); 13C NMR (CDCI3) δ
14.1, 22.5, 22.9, 28.6, 28.7, 29.4, 31.6, 32.7, 32.8, 47.4, 55.4, 170.1, 200.0; GC/MS 259 (M+l-Cl); MS (MALDI-TOF) 294 (M+l); IR (KBr) 3306, 2918, 2922, 1737, 1641, 1537, 1466, 1372, 1283, 1134 cm"1. N-Ac-S-octyl-cysteine chloromethyl ketone (4o, HI 352) Yellow solid.
Yield 30% yield, m.p. = 76-77 °C. Η NMR (CDCI3) δ 0.88 (t, J = 6.9 Hz, 3H), 1.2-1.4 (m, 10H), 1.55 (m, 2H), 2.05 (s, 3H), 2.53 (t, J= 7.4 Hz, 2H), 2.93 (m, 2H), 4.35 (m, 2H), 4.87 (m, IH), 6.36 (br d, IH); 13C NMR (CDCI3) δ 14.0, 22.5, 28.4, 29.3, 31.3, 32.7, 32.9, 47.3, 55.3, 170.0, 199.7; GC/MS 271 (M-HC1); IR (KBr) 3300, 3055, 2918, 2852, 1738, 1639, 1537, 1425, 1371, 1283 cm"1. N-Ac-S-nonyl-cysteine chloromethyl ketone (4p, HI 364) Yellow solid. Yield 35%. m.p. = 78-81 °C. 1H NMR (CDC13) δ 0.86 (t, J = 6.5 Hz, 3H), 1.2-1.4 (m, 12H), 1.58 (m, 2H), 2.06 (s, 3H), 2.56 (t, J = 7.3 Hz, 2H), 2.98 (ABX, J = 6.1, 6.3, 13.8 Hz, 2H), 4.36 (m, 2H), 4.86 (m, IH), 6.41 (br d, IH); 13C NMR (CDCI3) δ 14.1, 22.6, 22.9, 28.7, 29.1, 29.2, 29.4, 31.8, 32.7, 32.8, 47.4, 55.4, 170.2, 200.0; GC/MS 285 (M-HC1); MS (MALDI-TOF) 322 (M+l); IR (KBr) 3302, 2920, 2850, 1738, 1643, 1537, 1394 cm"1. N-Ac-S-decyl-cysteine chloromethyl ketone (4q, HI 371) Yellow solid.
Yield 10%. m.p. = 80-81 °C. Η NMR (CDC13) δ 0.86 (t, J= 6.7 Hz, 3H), 1.2-1.4 (m, 14H), 1.59 (m, 2H), 2.06 (s, 3H), 2.56 (t, J= 7.3 Hz, 2H), 2.98 (ABX, J = 6.0, 6.3, 13.7 Hz, 2H), 4.28 (m, 2H), 4.93 (m, IH), 6.21 (br d, IH); 13C NMR (CDCI3) δ 14.1, 22.7, 22.9, 28.7, 29.2, 29.3, 29.4, 29.5, 31.9, 32.8, 47.4, 55.4, 170.1, 200.0; MS (MALDI-TOF) 301 (M-Cl); IR (KBr) 3302, 2920, 2850, 1736, 1635, 1539, 1467 cm '.
N-Ac-S-undecyl-cysteine chloromethyl ketone (4r, HI 321) Yellow solid. Yield 25%. m.p. = 85-86 °C. 1H NMR (CDC13) δ 0.86 (t, J = 6.7 Hz, 3H), 1.2-1.4 (m, 16H), 1.59 (m, 2H), 2.06 (s, 3H), 2.56 (t, J = 7.3 Hz, 2H), 2.98 (ABX, J = 6.0, 6.3, 13.7 Hz, 2H), 4.28 (m, 2H), 4.93 (m, IH), 6.21 (br d, IH); 13C NMR (CDCI3) δ 14.1, 22.7, 22.9, 28.7, 29.2, 29.3, 29.4, 29.5, 29.6, 31.9, 32.8, 32.9, 47.4, 55.4, 170.1, 200.0; GC/MS 313 (M-Cl); MS (MALDI-TOF) 313 (M-Cl); IR (KBr) 3305, 2918, 2850, 1738, 1651, 1537, 1466 cm"1.
N-Ac-S-tridecyl-cysteine chloromethyl ketone (4s, HI 323) Yellow solid. Yield 22%. m.p. = 83-84 °C. 1H NMR (CDCI3) δ 0.87 (t, J = 6.3 Hz, 3H), 1.2-1.4 (m, 20H), 1.59 (m, 2H), 2.06 (s, 3H), 2.56 (t, J= 7.2 Hz, 2H), 2.98 (ABX, J = 5.8, 6.0, 14.0 Hz, 2H), 4.28 (m, 2H), 4.93 (m, IH), 6.21 (br d, IH); 13C NMR (CDCI3) δ 14.1, 22.7, 23.0, 28.8, 29.2, 29.4, 29.4, 29.5, 29.6, 31.9, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; GC/MS 341 (M-HC1); MS (MALDI-TOF) 379 (M+2); IR (KBr) 3307, 2916, 2850, 1737, 1651, 1537, 1466, 1402, 1282 cm"1.
N-Ac-S-tetradecyl-cysteine chloromethyl ketone (4t, HI 354) Yellow solid. Yield 32%. m.p. = 79-80 °C. 1H NMR (CDCI3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.2-1.4 (m, 22H), 1.57 (m, 2H), 2.06 (s, 3H), 2.51 (t, J- 7.3 Hz, 2H), 2.94 (ABX, J = 6.0, 6.3, 13.9 Hz, 2H), 4.35 (m, 2H), 4.90 (m, IH), 6.30 (br d, IH); 13C NMR (CDCI3) δ 14.1, 22.7, 22.9, 28.7, 29.2, 29.35, 29.4, 29.5, 29.6, 29.7, 31.9, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; GC/MS 355 (M-HC1); IR (KBr) 3302, 3259, 2916, 2848, 1738, 1660, 1537, 1464, 1373, 1317 cm"1.
N-Ac-S-pentadecyl-cysteine chloromethyl ketone (4u, HI 225) Yellow solid. Yield 25%. m.p. = 86-89 °C. Η NMR (CDC13) δ 0.86 (t, J = 6.5 Hz, 3H), 1.2-1.4 (m, 24H), 1.55 (m, 2H), 2.03 (s, 3H), 2.51 (t, J- 6.2 Hz, 2H), 2.91 (ABX, J = 6.0, 6.3, 14.0 Hz, 2H), 4.34 (m, 2H), 4.88 (m, IH), 6.33 (br d, IH); 13C NMR (CDCI3) δ 14.1, 22.7, 23.0, 28.8, 29.0, 29.2, 29.4, 29.5, 29.7, 30.7, 31.9, 32.2, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; GC/MS 369 (M-HC1); MS (MALDI-TOF) 407 (M+2); IR (KBr) 3307, 3124, 2916, 2850, 1738, 1651, 1533, 1487, 1404, 1284 cm"1. N— Ac-S-hexadecyl-cysteine chloromethyl ketone (4v, HI 366) Yellow solid. Yield 18%. m.p. = 87-88 °C. Η NMR (CDC13) δ 0.86 (t, J = 6.7 Hz, 3H), 1.2-1.4 (m, 26H), 1.55 (m, 2H), 2.03 (s, 3H), 2.51 (t, J= 7.3 Hz, 2H), 2.98 (ABX, J = 5.8, 6.0, 14.0 Hz, 2H), 4.32 (m, 2H), 4.93 (m, IH), 6.26 (br d, IH); 13C NMR (CDCI3) δ 14.2, 22.7, 23.0, 28.8, 29.0, 29.2, 29.4, 29.5, 29.7, 31.9, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; GC/MS 383 (M-Cl); MS (MALDI-TOF) 382 (M-HC1); IR (KBr) 3259, 2916, 2848, 1740, 1660, 1539, 1471, 1432, 1134 cm"1.
N-Ac-S-octadecyl-cysteine chloromethyl ketone (4w, HI 370) Yellow solid. Yield 78%. m.p. = 84-86 °C. JH NMR (CDCI3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.2-1.4 (m, 30H), 1.57 (m, 2H), 2.06 (s, 3H), 2.53 (t, J= 7.4 Hz, 2H), 2.94 (ABX, J = 5.8, 6.3, 13.7 Hz, 2H), 4.35 (m, 2H), 4.90 (m, IH), 6.31 (br d, IH); 13C NMR (CDCI3) δ 14.2, 22.7, 23.0, 28.8, 29.2, 29.35, 29.4, 29.5, 29.6, 29.7, 31.9, 32.8, 32.9, 34.4, 47.3, 55.4, 170.0, 200.0; IR (KBr) 3313, 2916, 2850, 1738, 1651, 1537, 1466, 1385, 1281, 1254 cm"1.
N-Ac-S-eicoyl-cysteine chloromethyl ketone (4x, HI 226) Yellow solid. Yield 11%. m.p. = 84-89 °C. Η NMR (CDCI3) δ 0.87 (t, J = 6.6 Hz, 3H), 1.2-1.4 (m, 34H), 1.55 (m, 2H), 2.04 (s, 3H), 2.52 (t, J = 7.9 Hz, 2H), 2.92 (ABX, J = 6.0, 7.7, 14.0 Hz, 2H), 4.32 (m, 2H), 4.92 (m, IH), 6.28 (br d, IH); 13C NMR (CDCI3) δ 14.2, 22.7, 23.0, 28.7, 29.2, 29.4, 29.5, 29.6, 29.7, 31.9, 32.8, 32.9, 47.3, 55.4, 170.0, 200.0; MS (MALDI-TOF) 477 (M+2); IR (KBr) 3307, 2918, 2850, 1736, 1662, 1541, 1464, 1261, 1097 cm"1. N-Ac-S-docosyl-cysteine chloromethyl ketone (4y, HI 322) Yellow solid. Yield 15%. m.p. = 95-97 °C. Η NMR (CDCI3) δ 0.88 (t, J = 6.5 Hz, 3H), 1.2-1.4 (m, 38H), 1.55 (m, 2H), 2.04 (s, 3H), 2.52 (t, J= 7.8 Hz, 2H), 2.92 (ABX, J = 6.0, 6.3, 14.0 Hz, 2H), 4.32 (m, 2H), 4.92 (m, IH), 6.28 (br d, IH); 13C NMR (CDCI3) δ 14.2, 22.7, 23.0, 28.8, 29.2, 29.4, 29.5, 29.7, 31.9, 32.8, 32.9, 47.3, 55.4, 170.1, 200.0; MS (MALDI-TOF) 493 (M+2-Cl+Na); IR (KBr) 3259, 2918, 2848, 1740, 1660, 1537, 1471, 1261, 1099 cm"1.
N-Ac-S-allyl-cysteine chloromethyl ketone (HI-419) Pale yellow solid: 1H NMR (CDCI3) δ 2.02 (s, 3H), 2.85 (m, 2H), 3.12 (d, 2H), 4.31 (m, 2H), 4.87 (m, IH), 5.12 (dd, IH), 5.16 (s, IH), 5.74 (m, IH), 6.32 (br, IH).
N-Ac-S-t-butyl-cysteine chloromethyl ketone (HI-349) Pale yellow solid: 1H NMR (CDC13) δ 1.24 (s, 9H), 1.97 (s, 3H), 2.90 (dd, 2H), 4.27 (m, 2H), 4.87 (m, IH), 6.32 (br, IH); MS (El) m/z 251 (M+).
N-Ac-S-2-methylpropyl-cysteine chloromethyl ketone (HI-391) Pale yellow solid: 1H NMR (CDC13) δ 0.94 (m, 6H), 1.74 (m, IH), 2.01 (s, 3H), 2.40 (d, 2H), 2.87 (t, 2H), 4.33 (m, 2H), 4.83 (m, IH), 6.51 (d, IH); MS (El) m/z 252 (M+).
N-Ac-S-2,2-dimethylpropyl-cysteine chloromethyl ketone (HI-421)
Pale yellow solid: Η NMR (CDC13) δ 1.32 (s, 9H), 2.06 (s, 3H), 3.15 (m, 2H), 3.45 (m, 2H), 4.34 (s, 2H), 4.94 (m, IH), 6.42 (d, IH); MS (El) m/z 227 (M - lBu). N-Ac-S-3-methylbutyl-cysteine chloromethyl ketone (HI-387) Pale yellow solid: !H NMR (CDC13) δ 0.89 (d, 6H), 1.44 (m, IH), 1.62 (m, 2H), 2.04 (s, 3H), 2.53 (t, 2H), 2.93 (m, 2H), 4.34 (m, 2H), 4.88 (m, IH), 6.30 (d, IH); MS (El) m/z 229 (M - CI).
N-Ac-S-2-ethylbutyl-cysteine chloromethyl ketone (HI-390) Pale yellow solid: 1H NMR (CDC13) δ 0.83 (m, 6H), 1.35 (m, 5H), 2.03 (s, 3H), 2.51 (d, 2H), 2.90 (m, 2H), 4.32 (d, 2H), 4.87 (m, IH), 6.34 (d, IH); MS (El) m/z 243 (M - CI).
N-Ac-S-cyclopropylmethyl-cysteine chloromethyl ketone (HI-507)
Pale yellow solid: 1H NMR (CDC13) δ 0.57 (d, 4H), 0.95 (m, IH), 2.03 (s, 3H), 2.45 (d, 2H), 2.97 (m, 2H), 4.33 (d, 2H), 4.89 (m, IH), 6.34 (d, IH).
N-Ac-S-cyclobutylmethyl-cysteine chloromethyl ketone (HI-385) Pale yellow solid: Η NMR (CDC13) δ 1.83 (m, 7H), 2.02 (s, 3H), 2.58 (d, 2H), 2.89 (m, 2H), 4.32 (d, 2H), 4.84 (m, IH), 6.32 (d, IH); MS (El) m/z 227 (M - CI). N-Ac-S-cyclohexylmethyl-cysteine chloromethyl ketone (HI-386) Pale yellow solid: 1H NMR (CDC13) δ 0.90 (m, 2H), 1.25 (m, 4H), 1.41 (m, 4H), 1.70 (m, IH), 2.04 (s, 3H), 2.40 (d, 2H), 2.89 (m, 2H), 4.34 (m, 2H), 4.86 (m, IH), 6.35 (d, IH). N-Ac-S-benzyl-cysteine chloromethyl ketone (HI-251) Pale yellow solid: Η NMR (CDC13) δ 1.98 (s, 3H), 2.82 (m, 2H), 3.70 (s, 2H), 4.08 (d, 2H), 4.82 (m, IH), 6.18 (d, IH), 7.29 (m, 5H).
N-Ac-S-4-methoxybenzyl-cysteine chloromethyl ketone (HI-349) Pale yellow solid: Η NMR (CDC13) δ 1.91 (s, 3H), 2.78 (m, 2H), 3.62 (s, 3H), 3.73 (s, 2H), 4.12 (d, 2H), 4.74 (m, IH), 6.07 (d, IH), 6.80 (m, 2H), 7.18 (m, 2H); MS (El) m/z 279 (M - CI).
N-Ac-S-benzyloxycarbonyl-cysteine chloromethyl ketone (HI-389) Pale yellow solid: 1H NMR (CDC13) δ 1.98 (s, 3H), 3.36 (m, 2H), 4.31 (d, 2H), 5.01 (m, 2H), 5.42 (m, IH), 6.43 (d, IH), 7.35 (m, 5H).
N-Ac-S-diphenylmethyl-cysteine chloromethyl ketone (HI-418) Pale yellow solid: Η NMR (CDC13) δ 2.00 (m, 4H), 3.37 (m, 2H), 4.34 (d, 2H), 5.02 (m, IH), 6.53 (d, IH), 7.30 (m, 10H).
N-Ac-S-trityl-cysteine chloromethyl ketone (HI-350) Pale yellow solid: 1H NMR (CDC13) δ 1.92 (s, 3H), 2.73 (m, 2H), 3.89 (s, 2H), 4.40 (m, IH), 5.82 (d, IH), 7.21 (m, 15H). N-Ac-S-2-naphthylmethyl-cysteine chloromethyl ketone (HI-392)
Pale yellow solid: Η NMR (CDC13) δ 1.89 (s, 3H), 2.81 (m, 2H), 3.84 (s, 2H), 4.13 (d, 2H), 4.83 (m, IH), 6.10 (d, IH), 7.43 (m, 2H), 7.66 (s, IH), 7.72 (m, 4H).
N-Ac-O-dodecyl-serine chloromethyl ketone (HI-489) White solid: H
NMR (CDCI3) δ 0.88 (t, 3H), 1.26 (m, 20H), 2.05 (s, 3H), 3.41 (t, 2H), 3.57 (m, IH), 3.88 (m, IH), 4.29 (d, 2H), 4.90 (m, IH), 6.32 (d, IH).
N-Boc-O-dodecyl serine chloromethyl ketone (HI-266) Pale yellow solid: 1H NMR (CDC13) δ 0.88 (t, 3H), 1.26 (m, 20H), 1.46 (s, 9H), 3.41 (t, 2H), 3.50 (m, IH), 3.57 (dd, IH), 4.37 (d, 2H), 4.56 (m, IH), 5.21 (d, IH); MS (El) m/z 357 (M - CI).
N-Propyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone (HI- 413) Pale yellow solid: Η NMR (CDC13) δ 0.92 (m, 6H), 1.25 (m, 20H), 1.60 (m, 2H), 2.52 (t, 2H), 2.91 (d, 2H), 4.01 (t, 2H), 4.45 (s, 2H), 4.66 (m, IH), 5.48 (d, IH); MS (El) m/z 371 (M - CI).
N-Benzyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone (HI- 320) Pale yellow solid: !H NMR (CDC13) δ 0.86 (t, 3H), 1.27 (m, 20H), 2.49 (t, 2H), 2.91 (d, 2H), 4.32 (s, 2H), 4.70 (m, IH), 5.19 (s, 2H), 5.59 (d, IH), 7.32 (s, 5H); MS (El) m/z 419 (M - CI).
N-9-Fluorenylmethyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone (HI-398) Pale yellow solid: 1H NMR (CDC13) δ 0.87 (t, 3H), 1.24 (m, 18H), 1.52 (m, 2H), 2.52 (t, 2H), 2.93 (m, 2H), 4.22 (t, IH), 4.28 (s, 2H), 4.46 (m, 2H), 4.68 (m, IH), 5.59 (d, IH), 7.35-7.77 (m, 8H).
N-3-Dimethylaminobenzoyl-S-dodecyl-cysteine chloromethyl ketone (HI-268) Pale yellow solid: 1H NMR (CDC13) δ 0.94 (t, 3H), 1.26 (m, 20H), 2.54 (t, 2H), 3.01 (d, 2H), 3.93 (d, 6H), 4.13 (d, 2H), 4.68 (m, IH), 5.53 (d, IH), 7.00 (dd, IH), 7.40 (m, 3H).
N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488) Pale yellow solid: Η NMR (CDC13) δ 0.84 (t, 3H), 1.22 (m, 18H), 1.53 (m, 2H), 2.02 (s, 3H), 2.50 (t, 2H), 2.92 (m, 2H), 4.12 (s, 2H), 4.89 (m, IH), 6.44 (d, IH).
N-Ac-S-dodecyl-Cys-N(OCH3)-CH3 (HI-267) Pale yellow oil: Η NMR (CDCI3) δ 0.87 (t, 3H), 1.25 (m, 20H), 2.02 (s, 3H), 2.51 (t, 2H), 2.82 (m, 2H), 3.22 (s, 3H), 3.79 (s, 3H), 5.17 (m, IH), 6.38 (d, IH); MS (El) m/z 314 (M - N(OCH3)CH3).
N-Ac-S-dodecyl-Cys-H (HI-274) White solid: 1H NMR (CDC13) δ 0.88 (t, 3H), 1.26 (m, 18H), 1.58 (m, 2H), 2.09 (s, 3H), 2.54 (t, 2H), 3.00 (m, 2H), 4.63 (m, IH), 6.37 (d, IH), 9.65 (s, IH). N-Ac-S-dodecyl-Cys-CH2-SPh (HI-269) Pale yellow solid: 1H NMR (CDCI3) δ 0.88 (t, 3H), 1.25 (m, 18H), 1.53 (m, 2H), 1.97 (s, 3H), 2.46 (t, 2H), 2.2 (m, 2H), 5.16 (m, IH), 5.43 (s, 2H), 6.16 (d, IH), 7.33 (s, 5H). N-Ac-S-dodecyl-Cys-CH2-S-2-naphthyl (HI-302) Pale yellow solid:
1H NMR (CDCI3) δ 0.81 (t, 3H), 1.16 (m, 18H), 1.39 (m, 2H), 1.84 (s, 3H), 2.36 (t, 2H), 2.77 (m, 2H), 5.18 (m, IH), 5.59 (s, 2H), 6.08 (d, IH), 7.43 (s, 3H), 7.73 (m, 4H).
N-Ac-S-dodecyl-Cys-CH2-S-CH2CH2CO2H (HI-273) White solid: Η
NMR (CDC13) δ 0.88 (t, 3H), 1.26 (m, 18H), 1.33 (m, 2H), 2.07 (s, 3H), 2.54 (t, 2H), 2.77 (m, 4H), 2.97 (m, 2H), 3.48 (m, 2H), 5.02 (m, IH), 6.44 (d, IH), 8.04 (br, IH).
Example 3
Cytotoxicity of alkyl ketone compounds The cytotoxicity of the alkyl ketone compounds against tumor cells was evaluated in leukemic cells, breast cancer cells, prostate cancer cells, and brain cancer cells.
Cytotoxicity Assay
Cytotoxicity of various compounds against tumor cells was performed using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Boehringer Mannheim Corp., Indianapolis, IN). Unless otherwise specified, all cell lines were obtained from the American Type Culture Collection (ATCC). Briefly, exponentially growing cells were seeded into a 96-well plate at a density of 2.5 x 104 cells/well and incubated for 36 hours at 37°C prior to drug exposure. On the day of treatment, culture medium was carefully aspirated from the wells and replaced with fresh medium containing the indicated compound at concentrations ranging from 0.1 to 250 μM. Triplicate wells were used for each treatment. Human leukemic cell lines (NALM-6, MOLT-3) glioblastoma cells
(U373) and human breast tumor cell lines (BT20 and MDA-MB-231) were obtained from the American Type Culture Collection and maintained as a continuous cell line in Dulbecco's modified Eagles 's medium supplemented with 10% fetal bovine serum and antibiotics. The cells were incubated with the various compounds for 24-36 hours at 37°C in a humidified 5% CO2 atmosphere. To each well, 10 μl of MTT (0.5 mg/ml final concentration) was added and the plates were incubated at 37°C for 4 hours to allow MTT to form formazan crystals by reacting with metabolically active cells. The formazan crystals were solubilized overnight at 37°C in a solution containing 10% SDS in 0.01 M HCI. The absorbence of each well was measured in a microplate reader (Labsystems) at 540 nm and a reference wavelength of 690 nm. To translate the OD 540 values into the number of live cells in each well, the OD 5 0 values were compared to those on standard OD 540 - versus - cell number curves generated for each cell line. The percent survival was calculated using the formula:
live cell number [test]
% Survival = IOO live cell number [control]
The ICso values were calculated by non-linear regression analysis and are shown below in Tables 1 - 6.
Table 1. Structure and activities of S-alkyl cysteine diazo and chloromethyl ketone derivatives against Nalm-6 (B-lineage ALL), Molt-3 (T- lineage ALL), BT-20 (breast cancer), PC-3 (prostate cancer) and U-373 (glioblastoma) cell lines.
Figure imgf000041_0001
Figure imgf000041_0002
3d >100 3e >100 13 71 3 4b >100 4a 61 3 4c >100 4 >100 4e 35 1 8 >100 9 >100
Figure imgf000042_0003
Figure imgf000042_0001
Figure imgf000042_0004
Table 2. Structure and activities of farnesylthio methyl ketone derivatives against Nalm-6 (B-lineage ALL), Molt-3 (T-lineage ALL), BT- 20 (breast cancer), PC-3 (prostate cancer) and U-373 (glioblastoma) cell lines.
Figure imgf000042_0002
Figure imgf000042_0005
Table 3. Comparison of the effect of the S-alkyl chain length upon the activities of cysteine chloromethyl ketone derivatives against Nalm-6 (B-lineage ALL) and Molt-3 (T-lineage ALL), BT-20 (breast cancer), PC-3 (prostate cancer) and U-373 (glioblastoma) cell lines
Figure imgf000043_0001
Figure imgf000043_0002
Table 4. Examination of the effect of changing RI of the molecule.
Figure imgf000044_0001
Figure imgf000044_0002
Table 5. Examination of the effect of changing X from S to O and altering R4.
Figure imgf000045_0001
Figure imgf000045_0003
Table 6. An examination of the effects of incorporating rings and branched chains into R3.
Figure imgf000045_0002
Figure imgf000046_0001
The data shown in Table I suggest that substitution at the RI position with a chloromethyl group is better than substitution with a diazomethyl group. Placement of the dodecyl and farnesyl groups at the R3 position produced compounds having the greatest cytotoxicity.
The effect changing the length of R2 are reported in Table 2. Omission of the sidegroup caused the cytotoxicity of the compounds to decrease. Additionally, compounds where R2 comprises two carbon atoms were more cytotoxic than compounds
A series of compounds was prepared with different aliphatic chain lengths in the R3 position to determine the effect of chain length on cytotoxicity. As shown in Table 3, compounds with chain lengths of about 5 to 15 were the most effective anti-cancer agents. Preferred lengths were chain lengths of about 11 to 12. Various groups were tested in the R1 position to further define effective anti- cancer compounds. The results are reported in Table 4. Substitution of a bromomethyl group at the R1 position produced the most effective compound, consistent with Table I where chloromethyl was the most effective compound. The effect of changing of X and R4 on cytotoxicity was examined and reported in Table 5. The data show that a small acetyl substituent as R4 produces a potent cytotoxicagent, as both absence of acetyl and substitution with a larger group caused a loss in potency. Substitution of R4 with benzoyl produced an effective compound. The effect of changing X to O is more complex, with the derivatives being comparable in some cell lines but different in others. The ether compounds may offer advantages in terms of stability, despite their lower cytotoxic potency.
Various substitutions of R3 were analyzed to determine the effects of branched and ring structures on cytotoxicity. The results demonstrate that ringed and branched structures are effective anti-cancer compounds.
Example 4
Cytotoxicity of HI-131 in Primary Cancer Cells The cytotoxicity of HI-131 against primary cancer cells was evaluated in leukemia cells taken from six children (Figure 1 A), using the MTT assay described for Example 3. The cells were exposed to HI-131 at concentrations ranging from 0 to 50 μM. Percent survival was calculated as described for Example 3 and plotted against the HI-131 concentration used in the experiment. A composite concentration survival curve was then prepared from the data (Figure IB).
The results clearly show a dose dependent cytotoxic effect of HI-131 in primary cancer cells taken from all six patients.
Example 5
HI-131 Induces Apoptosis of Leukemia Cells The ability of HI-131 to induce apoptosis cells was evaluated in human leukemia in NALM-6 cells and primary leukemic cells from 2 patients. Cells were treated with 50 μM compound HI-131 for 24 hours. After incubatin, the cells were harvested and analyzed for apoptosis by in situ TUNNEL analysis and confocal laser scanning microscopy as described in Sudbeck et al., 1999, Clin. Cancer Res., 5:1589-82. Controls were treated with vehicle alone.
The data are shown in Figures 2A-2F. Controls (Figures 2 A, 2C, and 2E) failed to induce apoptosis. In contrast treatment with HI-131 (Figures 2B, 2D, and
2F) greatly induced apoptosis in the NALM-6 and primary leukemic cells.
Induction of apoptosis was further evaluated in primary leukemic cells and established NALM-6 and MOLT-3 cell lines following treatment with HI-131.
Data are shown in Figure 3. Primary leukemia cells treated with vehicle alone typically displayed an apoptotic rate of approximately 25%, with one sample exhibiting the much higher rate of about 70%. The rate of apoptosis in the control treated NALM-6 and MOLT-3 cell lines was much lower at about 5%. The rate of apoptosis in all but one of the primary leukemic cell samples increased dramatically after treatment with HI- 131 with an approximately 4-fold induction of apoptosis being typical. HI-131 , induced apoptosis was much more dramatic in NALM-6 and MOLT-3 cells, with an approximately 20-fold induction of apoptosis.
Example 6 HI-131 Inhibits Tumor Cell Invasion
The ability of HI-131 to inhibit invasion by MDA-MB-231 breast cancer cells and U373 glioblastoma cells was evaluated.
Cell Invasion Assay
The in vitro invasiveness of MDA-MB-231 breast cancer cells and U373 glioblastoma cells was assayed using a previously published method which employs Matrigel-coated Costar 24-well transwell cell culture chambers ("Boyden chambers") with 8.0-μm-pore polycarbonate filter inserts (Albini, et al., 1987, Cancer Res., 47:3239-3245). The chamber filters were coated with 50 μg/ml of Matrigel matrix, incubated overnight at room temperature under a laminar flow hood and stored at 4°C. Matrigel matrix is made up of several components of the extracellular matrix (ECM), including collagens, laminin and proteo-glycans.
On the day of the experiment, the coated inserts were rehydrated with 0.5 ml serum-free DMEM containing 0.1% bovine serum albumin for 1-2 hours. To study the effects of HI-131 on invasiveness of glioblastoma and breast cancer cells, exponentially growing cells were incubated overnight with HI-131 at various concentrations ranging from 1 μM to 25 μM and 2.5 μM to 25 μM, respectively. The cells were trypsinized, washed twice with serum-free DMEM containing BSA, counted and resuspended at 1 x 105 cells/ml. 0.5 ml cell suspension containing 5 x 104 cells in a serum-free DMEM containing HI-131 or vehicle was added to the Matrigel-coated and rehydrated filter inserts. Next, 750 μl of NIH fibroblast conditioned medium was placed as a chemoattractant in 24-well plates and the inserts were placed in wells and incubated at 37°C for 48 hours. After the incubation period, the filter inserts were removed, the medium was decanted off and the cells on the top side of the filter that did not migrate were scraped off with a cotton-tipped applicator. The invasive cells that migrated to the lower side of the filter were fixed, stained with Hema-3 solutions and counted under microscope. Five to 10 random fields per filter were counted to determine the mean (±SE) values for the invasive fraction. The invasive fractions of cells treated with HI-131 were compared to those of DMSO treated control cells and the percent invading relative to the control was determined using the formula:
% Invading = 100 * Number of Adherent Drug Treated Cells Number of Adherent Control Cells
Each treatment condition was evaluated in duplicate in 3 independent experiments. IC50 values were calculated by non-linear regression analysis using Graphpad Prisin Software Version 2.0 (Graphpad Software Inc., San Diego, CA).
Results
As shown in Figures 4 and 5, MDA-MB-231 breast cancer cells and U373 glioblastoma cells were highly invasive in Matrigel-coated Boyden chambers. HI- 131 inhibited the invasion of both MDA-MB-231 breast cancer cells and U373 glioblastoma cells through the Matrigel matrix in dose-dependent fashion.
Example 7
HI-131 Inhibits Adhesion of Cancer Cells
The ability of HI-131 to inhibit adhesion of MDA-MB-373 and U373 Glioblastoma cells was evaluated.
During the multistep process of tissue invasion, tumor cells initially adhere to the extracellular matrix proteins via cell surface integrin receptors and then gain migratory capacity to enter the surrounding tissues. ECM proteins such as laminin, fibronectin, and type IV collagen are thought to play an important role in tumor cell attachment and migration. Laminin, fibronectin and collagen have been found in the basal lamina of blood vessels and in the glial limitans externa in the brain that promote the adhesion and invasion of tumor cells in situ (Carbonetto, 1984, Trends Neurosci., 7:382-387; Rutkaet al. J. Neurosurg, 69:155-170; Venstrom, et al, 1993, FASEB J, 7:996-1003). The effects of these ECM proteins on integrin- mediated U373 glioblastoma and MDA-MB-231 cell adhesion was examined.
Cell Lines
A human brain tumor cell line derived from an adult patient with glioblastoma, U-373 MG (Cat. #HTB-17) and MDA-MB-231 breast cancer cells (Cat. #HTB-26) were obtained from American Type Culture Collection (ATCC, Manassas, VA) and maintained in liquid culture using DMEM supplemented with 10% fetal bovine serum and antibiotics. Fibroblast conditioned medium was used as a source of chemoattractant in vitro invasion assays. Conditioned medium was prepared as described previously (Albini, et al, 1987, Cancer Res., 47:3239-3245). For the preparation of this conditioned medium NIH/3T3 embryonic fibroblasts (ATCC cat. #CRL-1658) were grown to 80% confluency in DMEM medium supplemented with 10% FBS and cultured for 24 hours in serum-free medium containing 0.5 μg/ml bovine serum albuminutes The culture supernatants were collected, centrifuged at 1000 x g for 15 minutes to remove cellular debris and used as conditioned medium. Adhesion Assays
In vitro adhesion assays were performed to (a) study the baseline adhesive properties of U373 glioblastoma and MDA-MB-231 breast cancer cells and (b) evaluate the effects of HI-131 on the adhesive properties of these cells. The plates for the adhesion assays were precoated with the extracellular matrix proteins laminin, fibronectin or type IV collagen (each at a final concentration of 1 μg/ml in PBS) overnight at 4°C and dried. On the day of the experiment, the wells were rehydrated and blocked with 10% bovine serum albumin in PBS for 1 hour at room temperature and used for the adhesion assays, as described below. To study the effects of HI-131 on glioblastoma and breast cancer cell adhesion, exponentially growing cells in DMEM were incubated with the compound HI-131 or with genistein at concentrations ranging from 10 μM to 50 μM and 5 μM to 25 μM respectively for 16 hours in a humidified 5% CO2 atmosphere. DMSO (0.1%o) was included as a vehicle control. After treatment, cells were detached from the flasks with 0.05%> trypsin (Life Technologies) resuspended in DMEM, incubated at 37°C for 2 hours to allow them to recover from the trypsinization stress and examined for their ability to adhere to plates precoated with ECM proteins. In adhesion assays, cells were centrifuged, washed twice with serum-free DMEM, counted and resuspended in serum-free DMEM to a final concentration of 2.5 x 10 cells/ml. One hundred μl of the cell suspension containing 2.5x 10 cells were added to each well and cells were allowed to adhere for 1 hour at 37°C in a humidified 5% CO2 atmosphere. The adherent fraction was quantitated using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays. In brief, after washing the wells, 10 μl of MTT (0.5 mg/ml final concentration) (Boehringer Mannheim Corp., Indianapolis, IN) was added to each well and the plates were incubated at 37°C for 4 hours to allow MTT to form formazan crystals by reacting with metabolically active cells. The formazan crystals were solubilized overnight at 37°C in a solution containing 10% SDS in 0.01 M HCI . The absorbance of each well was measured in a microplate reader (Labsystems) at 540 nm and a reference wavelength of 690 nm. To translate the OD5 o values into the number of cells in each well, the OD5 0 values were compared to those on standard OD54o-versus-cell number curves generated for each cell line. The adherent fraction of cells treated with HI-131 was compared to the DMSO-treated control cells and the percent adhesion relative to the control was determined.
Each treatment condition was evaluated in duplicate in 3 independent experiments. The IC50 values were calculated by non-linear regression analysis.
Results
As shown in Figures 6 and 7, control U373 glioblastoma cells adhered to plates precoated with laminin, fibronectin, or type IV collagen about equally. Similar results were obtained with MBA-MD-231 breast cancer cells. Treatment with HI-131 resulted in a dose-dependent loss of adhesion in both glioblastoma and breast cells (See Figures 6 and 7).
All publications, patents, and patent documents described herein are incorporated by reference as if fully set forth. The invention described herein may be modified to include alternative embodiments. All such obvious alternatives are within the spirit and scope of the invention, as claimed below.

Claims

We claim:
1. A compound of the formula I:
Figure imgf000053_0001
wherein p is an integer selected from 0 and 1 ;
X is O or S;
R1 is H, hydroxyl, (d - C30) alkyl, (Q - C30) alkenyl, (Ci - C30) haloalkyl, (d - C30) diazoalkyl, , -CH2 O-C(O)R5, -NR6R7, or -CH2 -S- R9 wherein R5 is independently aryl, (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) alkenyl, ( - C30) diazoalkyl, (Ci - C24) cycloalkyl, or (C\ - C 4) cycloalkenyl,
R6 is independently H, ( - C30) alkyl, (Ci - C30) haloalkyl, (d - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C24) cycloalkyl, or (Ci - C ) cycloalkenyl;
R7 is -OR8,
R8 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (d - C30) haloalkenyl, (Ci - C24) cycloalkyl, or (Ci - C24) cycloalkenyl;
R9 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C24) cycloalkyl, (Ci - C24) cycloalkenyl, or -R10CO2H; R10 is (Ci - C30) alkyl or (C, - C30) alkenyl,
R2 is Ci or C2;
R3 is (Ci - C30) alkyl, (C, - C30) haloalkyl, (Ci - C30) alkenyl, (C, - C30) haloalkenyl, (d - C24) cycloalkyl, (d - C24) cycloalkenyl, (Ci - C24)aryl, anthroquinonylmethyl, naphthylmethyl, -SR , or -CR ;
R11 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) alkenyl, or (Ci - C30) haloalkenyl;
R12 is aryl substituted methyl;
R4 is H, -C(O)R13, or -C(O)-O-R14;
R13 and R14 are each independently (Ci - C12) alkyl, (d - Cj2) haloalkyl, (C, - C12) alkenyl, (d - C12) haloalkenyl, (C3 - Cι2) cycloalkyl, or (C3 - C12) cycloalkenyl; or
a pharmaceutically acceptable acid addition salt thereof.
2. A compound of formula II:
Figure imgf000054_0001
wherein
X is O or S;
RI is H, hydroxyl, (C, - C30) alkyl, (d - C30) alkenyl, (Ci - C30) haloalkyl, (d - C30) diazoalkyl, , -CH2 O-C(O)R5, -NR6R7, or -CH2 -S- R9 wherein R3 is independently aryl, (Ci - C30) alkyl, (d - C30) haloalkyl, (Ci - C30) alkenyl, (Ci - C30) diazoalkyl, (Ci - C24) cycloalkyl, or
(Ci - C24) cycloalkenyl,
R6 is independently H, (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (d - C30) haloalkenyl, (d - C24) cycloalkyl, or (Ci - C24) cycloalkenyl;
R7 is -OR8,
R8 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (d - C30) alkenyl, (Ci - C30) haloalkenyl, (d - C24) cycloalkyl, or (Ci - C24) cycloalkenyl;
R9 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (d - C30) alkenyl, (Cj - C30) haloalkenyl, (Ci - C2 ) cycloalkyl, (Ci - C2 ) cycloalkenyl, or -R10CO2H;
R10 is (Ci - C30) alkyl or (Ci - C30) alkenyl, R2 is Cι or C2;
R3 is (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) alkenyl, (d - C30) haloalkenyl, (Ci - C2 ) cycloalkyl, (Ci - C24) cycloalkenyl, (d - C24)aryl, anthroquinonylmethyl, naphthylmethyl, -SR , or -CR ;
R11 is independently (d - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) alkenyl, or (Ci - C30) haloalkenyl;
R12 is aryl substituted methyl;
R4 is H, -C(O)R13, or -C(O)-O-R14;
R13 and R14 are each independently (Ci - C!2) alkyl, (Ci - C12) haloalkyl, (Ci - Cu) alkenyl, (C, - Ci2) haloalkenyl, (C3 - Ci2) cycloalkyl, or (C3 - Cπ) cycloalkenyl; or a pharmaceutically acceptable acid addition salt thereof.
3. A compound of formula III :
Figure imgf000056_0001
wherein
R1 is H, hydroxyl, (Ci - C30) alkyl, (Ci - C30) alkenyl, (d - C30) haloalkyl, (Ci - C30) diazoalkyl, , -CH2 O-C(O)R5, -NR6R7, or -CH2 -S- R9 wherein R5 is independently aryl, (Ci - C30) alkyl, (d - C30) haloalkyl, (Q - C30) alkenyl, (Ci - C30) diazoalkyl, (d - C24) cycloalkyl, or
(Ci - C24) cycloalkenyl,
R6 is independently H, (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - \ C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (Cj - C24) cycloalkyl, or (d - d4) cycloalkenyl;
R7 is -OR8,
R8 is independently (Cj - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Cj - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C24) cycloalkyl, or (Cj - C24) cycloalkenyl; R9 is independently (Ci - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C24) cycloalkyl, (Ci - C24) cycloalkenyl, or -R10CO2H;
R10 is (Ci - C30) alkyl or (d - C30) alkenyl; and R is C\ or C2; or a pharmaceutically acceptable acid addition salt thereof.
4. A compound of the formula IV:
Figure imgf000057_0001
(IV) wherein
R1 is H, hydroxyl, (Q - C30) alkyl, (Ci - C30) alkenyl, (d - C30) haloalkyl, (Ci - C30) diazoalkyl, , -CH2 O-C(O)R5, -NR6R7, or -CH2 -S-
R9 ;
R5 is independently aryl, (Ci - C30) alkyl, (d - C30) haloalkyl, (Ci - C30) alkenyl, (d - C 0) diazoalkyl, (d - C24) cycloalkyl, or (Ci - C2 ) cycloalkenyl;
R6 is independently H, (d - C30) alkyl, (Ci - C30) haloalkyl, (Ci - C30) diazoalkyl, (d - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C24) cycloalkyl, or (d - C24) cycloalkenyl;
R7 is -OR8;
R8 is independently (C, - C30) alkyl, (C, - C30) haloalkyl, (C, - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C2 ) cycloalkyl, or (Ci - C24) cycloalkenyl; R9 is independently (C, - C30) alkyl, (Ci - C30) haloalkyl, (C, - C30) diazoalkyl, (Ci - C30) alkenyl, (Ci - C30) haloalkenyl, (Ci - C2 ) cycloalkyl,
(Ci - C24) cycloalkenyl, or -R10CO2H;
R10 is (Ci - C30) alkyl or (Ci - C30) alkenyl; and
R2 is Ci or C ; or a pharmaceutically acceptable acid addition salt thereof.
5. The compound of claim 1, wherein R is a (d - C30) haloalkyl.
6. The compound of claim 5, wherein R is a (Ci - C30) chloroalkyl.
7. The compound of claim 1, wherein R is chloromethyl or bromomethyl.
8. The compound of claim 1, wherein R is (Cj - C30)diazoalkyl.
9. The compound of claim 1, wherein R is diazomethyl.
10. The compound of claim 1, wherein R3 is (Ci - C30) alkyl.
11. The compound of claim 1 , wherein R3 is selected from the group consisting of: acetyl, BOC, and BOC - amino acid.
12. The compound of claim 11, wherein said amino acid is Glycine.
13. The compound of claim 1, wherein R4 is methyl or ethyl.
14. The compound of claim 1, wherein p is 0.
15. The compound of claim 1 , wherein p is 1.
1
16. The compound of claim 1, wherein R is (Ci - C30) haloalkyl, R is (Ci —
C2) alkyl, R3 is (Cι-C30) alkyl, R4 is (d), and p is the integer 1.
17. The compound of claim 16, wherein R1 is chloroalkyl or bromoalkyl.
18. The compound of claim 16, wherein R1 is chloromethyl or bromomethyl.
19. The compound of claim 16, wherein R3 is (C12) alkyl.
20. The compound of claim 1, having the structure of N- Ac-S-dodecy 1-cys chloromethyl ketone (HI-131); or a pharmaceutically acceptable addition salt thereof.
21. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
22. A method for inhibiting growth of tumor cells in a subject comprising administering to said subject a compound of claim 1.
23. The method of claim 22, wherein said inhibiting comprises inducing apoptosis of said tumor cells.
24. A method of treating cancer in a subject comprising administering to said subject a compound of claim 1.
25. The method of claim 24, wherein said cancer is leukemia, breast cancer, prostate cancer, or brain tumor.
26. A method for inducing cytotoxicity in a cell comprising: administering to said cell a cytotoxic dose of the compound of claim 1.
27. The method of claim 26, wherein said cell is a cancer cell.
28. The method of claim 24, wherein said compound is:
N-Ac-S-trø ,-/rαra—farnesy 1-Cys diazomethyl ketone (HI-367); N—Ac-S-trans- trans-famesy 1-Cys chloromethyl ketone (HI-368); N-Ac-S-trøns—geranyl-Cys diazomethyl ketone (HI- 122); N-Ac-S-trø«s-geranyl-Cys chloromethyl ketone (HI- 127); N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (HI- 123); N-Ac-S-(3-methyl-2-butenyl)-Cys chloromethyl ketone (HI-128); N-Ac-S-dodecyl-Cys diazomethyl ketone (HI-348); N-Ac-S-dodecyl-Cys chloromethyl ketone (HI-131); N-Boc-S-farnesyl-Cys diazomethyl ketone (HI-82); N-Boc-S-farnesyl-Cys chloromethyl ketone (HI- 124); S-trα«s-tra«s-Famesyl-mercaptoethyl diazomethyl ketone (HI-83); S-trα«5-t «5-Farnesyl-2-mercaptoethyl chloromethyl ketone (H 125); S-trα»s-?raH£-Famesyl-mercaptomethyl diazomethyl ketone (HI-84); S-trαns- trans- Farnesyl-mercaptomethyl chloromethyl ketone (HI- 126); N-Boc-S-dodecyl-Cys chloromethyl ketone (H 129); S-Dodecyl-Cys chloromethyl ketone hydrochloride (HF-252); ~N-Boc~G\yS-trans- trans- farnesyl-Cys diazomethyl ketone (HI-401); N-Boc-Gly-S-?røra,-frøra— farnesyl-Cys chloromethyl ketone (HI-130); N-Ac-S-methyl-cysteine chloromethyl ketone (HI-314); N-Ac-S-ethyl-cysteine chloromethyl ketone (HI-315); N-Ac-S-propyl-cysteine chloromethyl ketone (HI-369); N-Ac-S-butyl-cysteine chloromethyl ketone (HI-363); N-Ac-S-pentyl-cysteine chloromethyl ketone (HI-224); N-Ac-S-hexyl-cysteine chloromethyl ketone (HI-357); N-Ac-S-heptyl-cysteine chloromethyl ketone (HI-263); N-Ac-S-octyl-cysteine chloromethyl ketone (HI-352); N-Ac-S-nonyl-cysteine chloromethyl ketone (HI-364); N-Ac-S-decyl-cysteine chloromethyl ketone (HI-371); N-Ac-S-undecyl-cysteine chloromethyl ketone (HI-321); N-Ac-S-tridecyl-cysteine chloromethyl ketone (HI-323); N-Ac-S-tetradecyl-cysteine chloromethyl ketone (HI-354); N-Ac-S-pentadecyl-cysteine chloromethyl ketone (HI-225); N-Ac-S-hexadecyl-cysteine chloromethyl ketone (HI-366); N-Ac-S-octadecyl-cysteine chloromethyl ketone (HI-370); N-Ac-S-eicoyl-cysteine chloromethyl ketone (HI-226); N-Ac-S-docosyl-cysteine chloromethyl ketone (HI-322); N-Ac-S-allyl-cysteine chloromethyl ketone (HI-419); N-Ac-S-t-butyl-cysteine chloromethyl ketone (HI-349); N-Ac-S-2-methylpropyl-cysteine chloromethyl ketone (HI-391); N-Ac-S-2,2-dimethylpropyl-cysteine chloromethyl ketone (HI-421); N-Ac-S-3-methylbutyl-cysteine chloromethyl ketone (HI-387); N-Ac-S-2-ethylbutyl-cysteine chloromethyl ketone (HI-390); N-Ac-S-cyclopropylmethyl-cysteine chloromethyl ketone (HI-507); N-Ac-S-cyclobutylmethyl-cysteine chloromethyl ketone (HI-385); N-Ac-S-cyclohexylmethyl-cysteine chloromethyl ketone (HI-386); N-Ac-S-benzyl-cysteine chloromethyl ketone (HI-251); N-Ac-S-4-methoxybenzyl-cysteine chloromethyl ketone (HI-349); N-Ac-S-benzyloxycarbonyl-cysteine chloromethyl ketone (HI-389); N-Ac-S-diphenylmethyl-cysteine chloromethyl ketone (HI-418); N-Ac-S-trityl-cysteine chloromethyl ketone (HI-350); N-Ac-S-2-naphthylmethyl-cysteine chloromethyl ketone (HI-392); N-Ac-O-dodecyl-serine chloromethyl ketone (HI-489); N-Boc-O-dodecyl serine chloromethyl ketone (HI-266); N-Propyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone (HI-413); N-Benzyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone (HI-320); N-9-Fluorenylmethyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone
(HI-398); N-3-Dimethylaminobenzoyl-S-dodecyl-cysteine chloromethyl ketone (HI- 268);
N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488); N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488); N-Ac-S-dodecyl-Cys-H (HI-274); N-Ac-S-dodecyl-Cys-CH2-SPh (HI-269); N-Ac-S-dodecyl-Cys-CH2-S-2-naphthyl (HI-302); N-Ac-S-dodecyl-Cys-CH2-S-CH2CH2CO2H (HI-273).
29. A compound of the formula:
N-Ac-S-trarø-frαra—farnesyl-Cys diazomethyl ketone (HI-367); N-AcS-trans- trans- farnesyl-Cys chloromethyl ketone (HI-368); N-Ac-S-rraw-gerany 1-Cys diazomethyl ketone (HI- 122); N-Ac-S-tra —gerany 1-Cys chloromethyl ketone (HI- 127); N-Ac-S-(3-methyl-2-butenyl)-Cys diazomethyl ketone (HI-123); N-Ac-S-(3-methyl-2-butenyl)-Cys chloromethyl ketone (HI-128); N-Ac-S-dodecyl-Cys diazomethyl ketone (HI-348); N-Ac-S-dodecyl-Cys chloromethyl ketone (HI-131); N-Boc-S-farnesyl-Cys diazomethyl ketone (HI-82); N-Boc-S-farnesyl-Cys chloromethyl ketone (HI-124); S-trαns-trαns-Famesyl-mercaptoethyl diazomethyl ketone (HI-83); S-trα ,-trαra,-Famesyl-2-mercaptoethyl chloromethyl ketone (HI-125); S-trα«5-trα«5-Farnesyl-mercaptomethyl diazomethyl ketone (HI-84); S-tr ra-rrαtti—Farnesyl-mercaptomethyl chloromethyl ketone (HP- 126); N-Boc-S-dodecyl-Cys chloromethyl ketone (HF-129); S-Dodecyl-Cys chloromethyl ketone hydrochloride (HP-252); N-Boc-Gly-S-/r « - rαra-farnesyl-Cys diazomethyl ketone (HI-401); N-Boc-G\yS-trans- trans-farnesy 1-Cys chloromethyl ketone (HI-130); N-Ac-S-methyl-cysteine chloromethyl ketone (HI-314); N-Ac-S-ethyl-cysteine chloromethyl ketone (HI-315); N-Ac-S-propyl-cysteine chloromethyl ketone (HI-369); N-Ac-S-butyl-cysteine chloromethyl ketone (HI-363); N-Ac-S-pentyl-cysteine chloromethyl ketone (HI-224); N-Ac-S-hexyl-cysteine chloromethyl ketone (HI-357); N-Ac-S-heptyl-cysteine chloromethyl ketone (HI-263); N-Ac-S-octyl-cysteine chloromethyl ketone (HI-352); N-Ac-S-nonyl-cysteine chloromethyl ketone (HI-364); N-Ac-S-decyl-cysteine chloromethyl ketone (HI-371); N-Ac-S-undecyl-cysteine chloromethyl ketone (HI-321); N-Ac-S-tridecyl-cysteine chloromethyl ketone (HI-323); N-Ac-S-tetradecyl-cysteine chloromethyl ketone (HI-354); N-Ac-S-pentadecyl-cysteine chloromethyl ketone (HT-225); N-Ac-S-hexadecyl-cysteine chloromethyl ketone (HI-366); N-Ac-S-octadecyl-cysteine chloromethyl ketone (HI-370); N-Ac-S-eicoyl-cysteine chloromethyl ketone (HI-226); N-Ac-S-docosyl-cysteine chloromethyl ketone (HI-322); N-Ac-S-allyl-cysteine chloromethyl ketone (HI-419); N-Ac-S-t-butyl-cysteine chloromethyl ketone (HI-349); N-Ac-S-2-methylpropyl-cysteine chloromethyl ketone (HI-391); N-Ac-S-2,2-dimethylpropyl-cysteine chloromethyl ketone (HI-421); N-Ac-S-3-methylbutyl-cysteine chloromethyl ketone (HI-387); N-Ac-S-2-ethylbutyl-cysteine chloromethyl ketone (HI-390); N-Ac-S-cyclopropylmethyl-cysteine chloromethyl ketone (HI-507); N-Ac-S-cyclobutylmethyl-cysteine chloromethyl ketone (HI-385); N-Ac-S-cyclohexylmethyl-cysteine chloromethyl ketone (HI-386); N-Ac-S-benzyl-cysteine chloromethyl ketone (HI-251); N-Ac-S-4-methoxybenzyl-cysteine chloromethyl ketone (HI-349); N-Ac-S-benzyloxycarbonyl-cysteine chloromethyl ketone (HI-389); N-Ac-S-diphenylmethyl-cysteine chloromethyl ketone (HI-418); N-Ac-S-trityl-cysteine chloromethyl ketone (HI-350); N-Ac-S-2-naphthylmethyl-cysteine chloromethyl ketone (HI-392); N-Ac-O-dodecyl-serine chloromethyl ketone (HI-489); N-Boc-O-dodecyl serine chloromethyl ketone (HI-266); N-Propyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone (HI-413); N-Benzyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone (HI-320); N-9-Fluorenylmethyloxycarbonyl-S-dodecyl-cysteine chloromethyl ketone
(HI-398); N-3-Dimethylaminobenzoyl-S-dodecyl-cysteine chloromethyl ketone (HI- 268);
N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488); N-Ac-S-dodecyl-cysteine bromomethyl ketone (HI-488); N-Ac-S-dodecyl-Cys-H (HI-274); N-Ac-S-dodecyl-Cys-CH2-SPh (HI-269); N-Ac-S-dodecyl-Cys-CH2-S-2-naphthyl (HI-302); N-Ac-S-dodecyl-Cys-CH2-S-CH2CH2CO2H (HI-273).
PCT/US1999/014758 1998-06-29 1999-06-29 Alkyl ketones as potent anti-cancer agents WO2000000469A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002336108A CA2336108A1 (en) 1998-06-29 1999-06-29 Alkyl ketones as potent anti-cancer agents
AU48459/99A AU754086B2 (en) 1998-06-29 1999-06-29 Alkyl ketones as potent anti-cancer agents
JP2000557230A JP2002519341A (en) 1998-06-29 1999-06-29 Alkyl ketones as potent anticancer agents
EP99932068A EP1091934A2 (en) 1998-06-29 1999-06-29 Alkyl ketones as potent anti-cancer agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9099798P 1998-06-29 1998-06-29
US60/090,997 1998-06-29
US9736398P 1998-08-21 1998-08-21
US60/097,363 1998-08-21

Publications (2)

Publication Number Publication Date
WO2000000469A2 true WO2000000469A2 (en) 2000-01-06
WO2000000469A3 WO2000000469A3 (en) 2000-06-15

Family

ID=26782863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/014758 WO2000000469A2 (en) 1998-06-29 1999-06-29 Alkyl ketones as potent anti-cancer agents

Country Status (5)

Country Link
EP (1) EP1091934A2 (en)
JP (1) JP2002519341A (en)
AU (1) AU754086B2 (en)
CA (1) CA2336108A1 (en)
WO (1) WO2000000469A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000483A2 (en) * 1998-06-29 2000-01-06 Parker Hugues Institute Tubulin binding compounds (cobra)
US6258841B1 (en) 1998-06-29 2001-07-10 Parker Hughes Institute Tubulin binding compounds (COBRA)
JP2003527364A (en) * 2000-03-03 2003-09-16 ティア、メディカ、アクチスカベット New fatty acid analogs
US6734207B2 (en) 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
US7214831B2 (en) 2002-05-22 2007-05-08 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
US9744147B2 (en) 2008-11-11 2017-08-29 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
AU2014346591B2 (en) * 2013-11-08 2018-09-27 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018465A2 (en) * 1991-04-15 1992-10-29 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
WO1995017512A2 (en) * 1993-12-23 1995-06-29 Cangene Corporation Proteases from streptomyces and use thereof in protein expression systems
WO1998022098A2 (en) * 1996-11-20 1998-05-28 Qlt Phototherapeutics, Inc. Cpp32 inhibitors for regulating apoptosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
JPH05117169A (en) * 1991-10-29 1993-05-14 Mitsubishi Kasei Corp Method for producing chloromethyl ketone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018465A2 (en) * 1991-04-15 1992-10-29 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
WO1995017512A2 (en) * 1993-12-23 1995-06-29 Cangene Corporation Proteases from streptomyces and use thereof in protein expression systems
WO1998022098A2 (en) * 1996-11-20 1998-05-28 Qlt Phototherapeutics, Inc. Cpp32 inhibitors for regulating apoptosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN, PING ET AL.: "A Practical Method for the Preparation of alpha'-Chloroketones of N-Carbamate Protected alpha-Aminoacids" TETRAHEDRON LETTERS, vol. 38, no. 18, 1997, pages 3175-3178, XP002120874 *
CHEN, YULONG ET AL.: "Solubilization, Partial Purification, and Affinity Labeling of the Membrane-Bound Isoprenylated Protein Endoprotease" BIOCHEMISTRY, vol. 35, no. 10, 1996, pages 3227-3237, XP002120873 *
DATABASE CHEMICAL ABSTRACTS [Online] ACS abstract no. 225574, 22 November 1993 (1993-11-22) ANDO, RYOICHI: "Preparation of chloromethyl ketones as inhibitors for serine and thiol protease" XP002120875 & JP 05 117169 A (MITSUBISHI CHEM. IND.) 14 May 1993 (1993-05-14) *
DATABASE CHEMICAL ABSTRACTS [Online] ACS Abstract no. 231845, 17 December 1990 (1990-12-17) INAZU, TOSHIYUKI & YAMANOI, TAKASHI: "Synthetic studies on D-erythro-C18-sphingosine" XP002120876 & NOGUSHI KENKYUSHO JIHO, no. 32, 1989, pages 13-26, *
JIA, ZONGCHAO ET AL.: "Crystal Structures of Recombinant Rat Cathepsin B and a Cathepsin B-Inhibitor Complex" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 10, 10 March 1995 (1995-03-10), pages 5527-5533, XP002120872 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000483A2 (en) * 1998-06-29 2000-01-06 Parker Hugues Institute Tubulin binding compounds (cobra)
WO2000000483A3 (en) * 1998-06-29 2000-09-28 Parker Hugues Inst Tubulin binding compounds (cobra)
US6258841B1 (en) 1998-06-29 2001-07-10 Parker Hughes Institute Tubulin binding compounds (COBRA)
US6329420B1 (en) 1998-06-29 2001-12-11 Parker Hughes Institute Tubulin binding compounds (COBRA)
JP2003527364A (en) * 2000-03-03 2003-09-16 ティア、メディカ、アクチスカベット New fatty acid analogs
US7037937B2 (en) 2001-04-20 2006-05-02 Parker Hughes Institute Cytotoxic compounds
US6734207B2 (en) 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
US7214831B2 (en) 2002-05-22 2007-05-08 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
US9744147B2 (en) 2008-11-11 2017-08-29 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
US10314802B2 (en) 2008-11-11 2019-06-11 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
AU2014346591B2 (en) * 2013-11-08 2018-09-27 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10112897B2 (en) 2013-11-08 2018-10-30 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10358414B2 (en) 2013-11-08 2019-07-23 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
AU2018282446B2 (en) * 2013-11-08 2020-07-23 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10961187B2 (en) 2013-11-08 2021-03-30 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds

Also Published As

Publication number Publication date
JP2002519341A (en) 2002-07-02
CA2336108A1 (en) 2000-01-06
WO2000000469A3 (en) 2000-06-15
AU4845999A (en) 2000-01-17
AU754086B2 (en) 2002-11-07
EP1091934A2 (en) 2001-04-18

Similar Documents

Publication Publication Date Title
US20090264487A1 (en) Hemiasterlin analogs
US6734207B2 (en) Cytotoxic compounds
KR100667464B1 (en) Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
KR20010021536A (en) Use of colchinol derivatives as vascular damaging agents
US6482816B1 (en) Organic arsenic compounds
US6251882B1 (en) Alkyl ketones as potent anti-cancer agents
WO2007059118A1 (en) Combretastatin derivatives and related therapeutic methods
AU754086B2 (en) Alkyl ketones as potent anti-cancer agents
US4904680A (en) Amino acid derivatives having anti-tumor activity and compositions containing them
KR101068259B1 (en) Novel betulinic acid derivatives a­ring­condensed to a heterocyclic group
US20170183297A1 (en) Omega-3 analogues
JPS6326748B2 (en)
JP4933683B1 (en) Novel retinoid derivatives having cytotoxic and / or anti-angiogenic properties
PL184861B1 (en) Improvement in tolerance of pharmaceutically active beta-amino acids
AU2013350311A1 (en) Omega-3 analogues
JPH03500880A (en) Renin inhibitors, methods for their production, methods for their use and compositions containing them
JPH03148246A (en) Peptidyldifluorodiol renin inhibiting substance
AU636090B2 (en) Esters of 2-arylmethyl-1-naphthol derivatives as 5-lipoxygenase inhibitors
US6686344B1 (en) Organic-arsonic compounds
WO1998042700A1 (en) N-(arginyl)benzenesulphonamide derivatives and use thereof as antithrombotic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 48459/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 557230

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2336108

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999932068

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999932068

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999932068

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 48459/99

Country of ref document: AU